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ABSTRACT 
Autotaxin (ATX) is a secreted enzyme responsible for the hydrolysis of lysophosphatidylcholine 
(LPC) to the bioactive lysophosphatidic acid (LPA) and choline. The ATX-LPA signalling 
pathway is implicated in cell survival, migration, and proliferation; thus, the inhibition of ATX is 
a recognized therapeutic target for a number of diseases including fibrotic diseases, cancer, and 
inflammation, amongst others. Many of the developed synthetic inhibitors for ATX have 
resembled the lipid chemotype of the native ligand; however, a small number of inhibitors have 
been described that deviate from this common scaffold. Herein, we report the structure-activity 
relationships (SAR) of a previously reported small molecule ATX inhibitor. We show through 
enzyme kinetics studies that analogues of this chemotype are noncompetitive inhibitors, and 
using a crystal structure with ATX we confirm the discrete binding mode.  
 
INTRODUCTION 
Autotaxin (ATX) is a secreted glycoprotein phosphodiesterase belonging to the ectonucleotide 
pyrophosphatase and phosphodiesterase family (ENPP).1 ATX mediates the hydrolysis of 
lysophosphatidylcholine (LPC) 1 to the ubiquitous bioactive lipid mediator lysophosphatidic 
acid (LPA) 2 and choline 3 (Scheme 1).2 2 acts on the LPA receptors; a series of G-protein 
coupled receptors (GPCRs), of which six have been identified to date, termed LPA1-6, with an 
additional three pending the publication of evidence to verify their categorization (GPR87, 
P2Y10, and GPR35).3 Upon binding, a series of intracellular signaling pathways are invoked 
which could result in a range of cellular functions including differentiation, migration, 
proliferation, and survival.4 Deregulation of the ATX-LPA signaling pathway is implicated in a 
variety of disease states and could lead to the development of several diseases including 
vascularization diseases, autoimmune diseases, cancer, fibrotic diseases, inflammation, and 
neurodegeneration, amongst others.5-10 Accordingly, the use of ATX inhibitors has been and 
continues to be an attractive strategy for therapeutic intervention (for a recent review see 
Castagna et al.11).  
 
Scheme 1. ATX-Mediated Hydrolysis of LPC Releasing LPA: Disease States via LPA Action on 
the GPCRs LPA1-6. R group = fatty acid chain with varying degrees of unsaturation. 
 With respect to the endogenous ligand (1), it is perhaps unsurprising that many of the synthetic 
ligands developed for ATX have resembled the lipid chemotype: an acidic ÔheadÕ group linked 
through a variety of ÔcoresÕ to a lipophilic ÔtailÕ (Figure 1: 4, 5, 6, and 7).12 However, a 
comparatively smaller number of inhibitors have been described that deviate from this common 
scaffold, for example PAT-347 (8), reported by PharmAkea Therapeutics.13 Lipid-based 
inhibitors have been previously reported to bind within the catalytic site of ATX and thus 
compete for the same region that the natural ligand is known to bind;17 however, a recent report 
from PharmAkea found the small molecule inhibitor 8 to be a potent noncompetitive inhibitor of 
ATX, with a distinct mode of binding remote to the catalytic site.13 This compound was noted to 
have a scaffold similar to our compound of interest, the indole-derived inhibitor 9 originally 
reported by Amira Pharmaceuticals.18 The patent in which 8 and related analogues are claimed 
report the IC50 values in ≤0.5 µM, >0.5 but ≤3 µM, or >3 µM categories;
13 similarly, the patents 
in which analogues of 9 are reported also categorize the activities (IC50 <300 nM, 0.3-1 µM, or 
>1 µM).18 From consideration of this data very little detailed SAR of these non-lipid-like ATX 
inhibitors can be extracted. Based on this, we generated a focused set of 50 analogues to explore 
the SAR of 9 in greater detail and to determine the features which contribute to its potency. 
 Figure 1. Lipid-Based Inhibitors and Small Molecule Inhibitors of ATX: 4,14 5,15 6,16 7,17 8,13 9 
(previously reported activity from patent literature).18 a FS-3 assay; b LPC choline release assay. 
 
Herein, we report the design, synthesis, and biological evaluation of our compound collection 
and describe the main determinants of potency regarding these indole-based compounds. We 
show that this chemotype has only limited activity in a bis-(p-nitrophenol) phosphate (bis-pNPP) 
based assay; however, using an LPC choline release assay a number of potent inhibitors were 
identified. Analysis of this data, combined with further kinetic studies into the mode of ATX 
inhibition, has furnished a new insight into the binding site of this chemotype. Furthermore, we 
report the crystal structure of ATX in complex with an analogue of 9, confirming that this 
chemotype binds in the same discrete binding site identified by PharmAkea in the cocrystal of 8 
with ATX.13 
ATX Inhibition Assays. There are a number of in vitro assays that are currently used to evaluate 
ATX activity; these can be divided into two categories based on the type of substrate the assay 
utilizes (Table 1). The first category employs the natural ligand 1 and the second uses unnatural 
ATX substrates. As depicted in Scheme 1, ATX hydrolyzes 1 into 2 and 3, thus the enzyme 
activity can be determined by quantitative measurement of these products using liquid 
chromatography-tandem mass spectrometry (LCMS), radiometry, colorimetry, or fluorimetry.19 
 
Table 1. Summary of ATX inhibition assays. 
Category Substrate Analysis 
Natural Substrate LPC LCMS,19a radiometry,19b colorimetry,19c 
fluorimetry19d  
Unnatural Substrate pNP-TMP2 Absorbance 
 bis-pNPP17 Absorbance 
 CPF420 FRET 
 FS-321 Fluorescence 
 TG-mTMP22 Fluorescence 
 
Of assays based on 1, a commonly used method measures the production of 3 using an enzyme-
coupled colorimetric assay19c Ð choline oxidase converts 3 into betaine 10 and hydrogen 
peroxide, and then horseradish peroxidase (HRP) utilizes the hydrogen peroxide to oxidize a 
coloring substrate into its chromophoric state (Scheme 2). There is a risk of false positives 
associated with this assay as the molecules under analysis may inhibit the enzymes used in the 
coloring reactions; 23 however, control reactions can be employed to reveal any interference.  
 
Scheme 2. ATX-mediated choline release colorimetric assay for ATX Inhibition. R group = fatty 
acid chain with varying degrees of unsaturation. 
 
  
Accordingly, assays that employ synthetic substrates can appear to be advantageous over the 
LPC choline release assay as they do not require the use of these additional enzymes. There are a 
number of unnatural substrates widely used, including the nucleotide thymidine 
5Õmonophosphate p-nitrophenyl ester (pNP-TMP),2 the Frster resonance energy transfer 
(FRET) ligand CPF4,20 the fluorogenic substrate 3 (FS-3),21 and the fluorescence probe 
TokyoGreen m-thymidine monophosphate (TG-mTMP).22 A particularly widely used method 
employs the unnatural substrate bis(p-nitrophenyl) phosphate (bis-pNPP) 11. ATX catalyses the 
hydrolysis of 11 to release 4-nitrophenol 12 which, with an absorbance of 405 nm, is readily 
detected using colorimetry (Scheme 3). The popularity of this assay can be attributed to the low 
cost of this substrate and the direct readout the assay provides.17 
 
Scheme 3. ATX-Mediated Hydrolysis of Bis-pNPP 11 Releasing 4-Nitrophenol 12. 
 
 
The recent report from PharmAkea Therapeutics described four structurally distinct ATX 
inhibitors that showed good inhibition using the LPC choline release assay but significantly 
lower potency when tested using the bis-pNPP or FS-3 substrates.13 The differences in datasets 
of the three assays used were found to be a result of alternative binding modes within ATX, 
which was confirmed by crystallographic data identifying proximal binding sites. As stated 
above, these compounds were noted to have a scaffold similar to our compound of interest, the 
indole-derived inhibitor 9 originally reported by Amira Pharmaceuticals. In the choline release 
assay employed by Amira Pharmaceuticals, 9 is claimed to show an IC50 of <300 nM, however, 
no further detail was given.18 In addition, 9 was reported to have activity in a mouse air pouch 
assay, collagen-induced arthritis, a rat model of neuropathic pain, and in lung melanoma 
metastasis, although the efficacy of 9 in these assays was not disclosed. Herein, we report that 9 
and related analogues were found to display only limited activity in the bis-pNPP assay; 
however, using the LPC choline release assay a number of efficient inhibitors were identified, 
with IC50 values ranging from 4 nM to >30 µM for the complete series. The disconnect observed 
between the two assay datasets for this chemotype were hypothesized to be due to an alternative 
binding mode, remote to the catalytic site. We report enzyme kinetic studies and a co-crystal 
structure of ATX with an analogue of 9 to support this alternative binding site. Furthermore, we 
also report the exploration of the SAR associated with this chemotype.  
Molecule Design. Using the limited data available, the key structural motifs of 9 were suspected 
to be (i) the chloro substitution at the 6-position of the indole, (ii) the substitution of the indole 
nitrogen, and (iii) the thiopyridine carboxylic acid. From this analysis we were able to infer the 
initial SAR shown in Figure 2. In the current study, we aimed to probe this emerging SAR 
further, to test our observations, and to more completely establish the contribution of each of 
these principal structural motifs towards potency through the synthesis and biological evaluation 
of a series of analogues.  
 
Figure 2. SAR of indole 9 extracted from data reported by Amira Pharmaceuticals.18  
The first region of interest was the 6-Cl substitution of the indole ring. Analysis of the patent 
data had suggested this was an important region of the molecule, with changes to substituent or 
position on the ring having a direct effect on the activity observed. To explore this relationship in 
greater depth, a series of compounds were designed with alternative chloro regiochemistry, as 
well as removal or exchange of the chloro for alternative functional groups. Three alternatives 
were chosen to determine the optimal size and nature of the substituent: fluoro, methoxy, and 
methyl. The second region to be modified was at the N-1 position of the indole ring. The N-
methyl pyrazole was replaced with a phenyl ring, cyclopentyl, and methyl to explore the 
tolerance of this region for a less polar aromatic ring as well as aliphatic groups. Finally, the 
thiopyridine carboxylic acid was modified, with changes made to the linker and the nature of the 
aromatic ring. The previously reported data in the patent literature contained little SAR around 
the linker area of the compound and therefore we were interested in converting the thioether to 
an ether or methylene linker, as well as exploring the difference between pyridyl and phenyl 
analogues. 
Chemistry. The known ATX inhibitor indole 9 was prepared as shown in Scheme 4. Starting 
from ketone 13,24 the indole was synthesized using a Fischer synthesis as previously reported, 
either according to or modified from literature procedures.18 This reaction produced a mixture of 
the 4-Cl and 6-Cl substituted indoles, which were successfully separated on silica to isolate the 
desired 6-Cl regioisomer 16 as the major product. The 4-Cl analogue 14 was also carried through 
the synthesis as part of the SAR study around the indole substitution. Introduction of the 1-
methyl-pyrazole substitution to the indole nitrogen proved to be challenging, requiring harsh 
conditions and long reaction times during which partial hydrolysis of the ester occurred. As a 
result, the substitution reaction was telescoped into the final step to fully hydrolyze the ester and 
produce the desired acid 9. 
 
Scheme 4. Synthesis of the Amira Compound 9.a 
 
aReagents and conditions: (a) (i) tBuOH, 3-chlorophenylhydrazine hydrochloride, reflux; (ii) 
HCl, AcOH; (b) 2 M aq. NaOH, THF, RT; (c) 4-iodo-1-methylpyrazole, K2CO3, CuO, pyridine, 
170 ¡C. 
Initial syntheses followed the reported methods from the Amira Pharmaceuticals patents to 
produce the desired indole 16 in good yield (71%, see experimental section) (Scheme 4). 
However, in the exploration of this key step it was discovered that a number of the Fischer 
indole reactions proceeded by refluxing the ketone with the respective hydrazine hydrochloride 
in EtOH without an additional acid catalyst (see experimental section). The synthesis of 
analogues in which the chloro was exchanged for an alternative functionality (F, OMe, and Me) 
was achieved using the same synthetic strategy employed in the synthesis of compound 9. Using 
this synthetic route, the analogues described in Figure 3 were accessed. Unfortunately, synthesis 
of the 7-Cl analogue with the 1-methyl-pyrazole N-substituent was not achieved, as efforts to 
introduce the 1-methyl-pyrazole were unsuccessful. 
   
Figure 3. Substitution on the indole ring.       
 
The next series was designed to investigate the SAR associated with the 1-methyl-pyrazole 
substituent on the indole nitrogen. In place of the 1-methyl-pyrazole three alternative substituents 
were used; methyl, cyclopentyl, and phenyl. The aliphatic substituents were introduced by an 
alkylation reaction using the corresponding alkyl halide and NaH (Scheme 5).  
 
Scheme 5. Synthesis of Compound 37.a 
 
aReagents and conditions: (a) (i) tBuOH, phenylhydrazine hydrochloride, reflux; (ii) HCl, 
AcOH; (b) NaH, MeI, THF, reflux; (c) 2 M aq. NaOH, THF, RT. 
 
Following the alkylation step, hydrolysis of the corresponding ester revealed the desired 
carboxylic acid. The phenyl substituent was introduced using an alternative Ullmann coupling 
and the 1-methyl-pyrazole was introduced using the conditions described previously. Using these 
approaches, the analogues described in Figure 4 were successfully synthesized. 
      
Figure 4.  Substitution on the indole nitrogen.   
 
The benzoic acid compounds were synthesized in a similar way to the pyridyl series with an 
additional step to introduce the ester functionality using a methoxycarbonylation reaction 
(Scheme 6). From this intermediate the desired alkyl or aryl N-substituent was introduced, 
followed by hydrolysis to gain the desired acid 47 in the final step of the synthesis. The ester 46, 
and its deschloro counterpart 92 (not shown, see experimental section), then allowed access to 
the analogues described in Figure 5. 
Scheme 6. Synthesis of Compounds 45-48.a 
 
aReagents and conditions: (a) chloroacetone, DIPEA, MeCN, reflux; (b) 3-
chlorophenylhydrazine hydrochloride, EtOH, reflux; (c) HerrmannÕs catalyst, Mo(CO)6, 
[tBu3PH]BF4, DBU, MeOH/MeCN (1:4), 70 ¡C; (d) NaH, MeI, THF, reflux; (e) 2 M aq. NaOH, 
THF, RT. 
 
Figure 5. Substitution on the indole nitrogen, benzoic acid analogues. 
 
The oxygen-linked benzoic acid subset (Figure 6) were synthesized using the Fischer indole 
reaction that was employed with previous analogues (Scheme 7). Efforts to synthesize the 
corresponding ether linked pyridyl compounds were unsuccessful (see Electronic Supporting 
Information (ESI)). 
 
Scheme 7. Synthesis of Compounds 59-62.a 
 
aReagents and conditions: (a) chloroacetone, K2CO3, acetone, reflux; (b) phenylhydrazine 
hydrochloride, EtOH, reflux; (c) 2 M aq. NaOH, THF, RT; (d) 4-bromo-1-methylpyrazole, 
K2CO3, CuO, pyridine, 170 ¡C.  
 Figure 6. Ether linked analogues. 
 
In order to access the methylene linked compounds an alternative synthetic strategy was required 
as efforts to employ a Fischer indole synthesis were unsuccessful. It was discovered that by 
reordering the synthetic steps to install the 1-methyl-pyrazole at an earlier stage, the N-
substitution proceeded in a much improved yield than the late stage introduction used in previous 
syntheses (Scheme 8). A two-step alkylation of 66 using 6-bromopicolinaldehyde afforded the 
desired methylene linker in good yield. From the bromo intermediate 97 (not shown) the ester 
functionality was introduced via a methoxycarbonylation reaction to give 67, followed by 
hydrolysis to reveal the desired acid 68. Thus, this strategy was used to access the remaining 
compounds in this series (Figure 7).  
 
Scheme 8. Synthesis of Compounds 66-68.a 
 
aReagents and conditions: (a) 4-bromo-1-methylpyrazole, K2CO3, CuO, pyridine, 170 ¡C; (b) (i) 
6-bromopicolinaldehyde, CH2Cl2 (ii) Et3SiH, TFA, CH2Cl2; (c) HerrmannÕs catalyst, Mo(CO)6, 
[tBu3PH]BF4, DBU, MeOH/MeCN (1:4), 70 ¡C; (d) 2 M aq. NaOH, THF, RT. 
 
Figure 7. Methylene linked analogues. 
	
To determine the importance of the indole core, this motif was removed and compound 75 was 
prepared featuring a phenyl at its center but retaining the 1-methyl-pyrazole motif. This 
compound was obtained from the commercial carboxylic acid 72 in four steps (Scheme 9). This 
required an alternative strategy, using a Suzuki-Miyaura reaction to introduce the 1-methyl-
pyrazole via the coupling of 74 with 1-methylpyrazole-4-boronic acid pinacol ester.  
	
Scheme 9. Synthesis of Analogue 75.a 
 
aReagents and conditions: (a) conc. H2SO4, MeOH, reflux; (b) 4-bromothiophenol, DMF, 45 ¡C; 
(c) 1-methylpyrazole-4-boronic acid pinacol ester, K3PO4, Pd(OAc)2, SPhos, THF/H2O (7:1), 50 
¡C; (d) 2 M aq. NaOH, THF, RT. 
 
The final deletion analogue was designed to remove one of the aromatic rings from the 
compound and replace it with an aliphatic carboxylic acid (Scheme 10). Starting from 4-
bromobutyric acid 76 the thiol group was introduced by an S-alkylation of thiourea, which was 
subsequently hydrolyzed in situ to form the primary thiol 77. This was then followed by a second 
alkylation using chloroacetone to access the Fischer indole precursor 78. With 79 in hand, the 1-
methyl-pyrazole was introduced at the indole nitrogen (Scheme 10). This route was also 
employed to access the 6-Cl analogue 81 (Figure 8). 
 
Scheme 10. Synthesis of Aliphatic Carboxylic Acid Analogue 80.a 
 
aReagents and conditions: (a) thiourea, EtOH, reflux; (b) chloroacetone, DIPEA, THF, RT; (c) 
phenylhydrazine hydrochloride, EtOH, reflux; (d) 4-bromo-1-methylpyrazole, K2CO3, CuO, 
pyridine, 170 ¡C. 
 
Figure 8. Aliphatic acid analogues. 
 
Results and Discussion. To evaluate our compound library, the first screen was performed using 
the bis-pNPP assay. This was selected based on its broad application throughout the ATX 
literature.11 An initial screen was carried out using 30 µM of inhibitor allowing a rapid 
evaluation of the compounds. The criteria of >60% inhibition was set for a compound to be 
termed active and therefore progressed to further testing. Based on this initial survey of the 
activity of Amira compound 9 along with the 49 analogues in the bis-pNPP assay, we identified 
10 potential inhibitors, including the patent compound 9 (see ESI). These 10 compounds were 
tested again in the bis-pNPP assay using a concentration range of 30 nM Ð 30 µM inhibitor, to 
determine the IC50 for each of these compounds. Using the bis-pNPP assay, the Amira ATX 
inhibitor 9 was found to have an IC50 of 22 nM, which was consistent with the value of <300 nM 
claimed in the patent (LPC choline release assay);18 however, the IC50 values observed in this set 
ranged from 22 nM to >30 µM (Table 2). These results demonstrated that our first screen at an 
inhibitor concentration of 30 µM had not been a reliable indicator of activity. Importantly, on 
further inspection of the dose response curves (Figure 9), it was noted that when using the bis-
pNPP assay, compound 9 showed only 66% maximal inhibition of ATX at 30 µM (34% 
hydrolysis of 11), indicating that this analogue was not fully inhibiting the ATX hydrolysis of 
11, potentially implying a discrete binding mode compared to that of the artificial substrate.  
9
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Figure 9. Testing of 9 in the bis-pNPP assay from 30 nM Ð 30 µM of inhibitor. Dashed line 
indicates 60% inhibition criteria of initial screen. Control reactions confirmed there was no 
hydrolysis of 11 in the absence of ATX (data not shown).  
 
A further 20 analogues were tested in the bis-pNPP assay confirming that partial inhibition was a 
consistent feature associated with this series (data not shown, see ESI). Although the bis-pNPP 
assay has many advantages, there are risks associated with the use of unnatural substrates if the 
binding interactions with the target enzyme are dissimilar to those of the natural substrate. There 
are a number of reported examples where misleading results were observed when using ATX 
assays that employ the unnatural ligands FS-3, CPF4, and pNP-TMP.17,25,26 The authors 
concluded that the discrepancies in assay datasets were the result of the inhibitor compounds and 
assay substrates binding to different regions of ATX. It has been well documented that the active 
site of ATX features three key regions with which small molecule inhibitors can interact: the 
catalytic site, the hydrophobic pocket, and the tunnel.27-29 Comparing the likely binding of the 
unnatural substrate 11 with that of ATX in complex with 2, it is noted that while both bind at the 
catalytic site, the acyl chain of 2 shows additional extensive interactions with the hydrophobic 
pocket (Figure 10). This suggests that it is possible for small molecules to bind outside the 
catalytic site without inhibiting, or only partially inhibiting, the hydrolysis of 11, potentially 
resulting in false negative results in the bis-pNPP ATX assay. 
 
 Figure 10. Three binding sites of ATX: Catalytic Site, Hydrophobic Pocket, and Tunnel. 
Complex of LPA 14:0 (red) in mouse ATX (PDB 3NKN) with the docked position of bis-pNPP 
11 (green) overlaid. Docked using GOLD30 and viewed using Discovery Studio Visualizer.31  
 
Indeed, the noncompetitive inhibitor 8 from PharmAkea, which shares a number of structural 
similarities to 9, has been reported to bind an allosteric site within the tunnel.13 The authors 
observed that 8 inhibited the hydrolysis of 1 but not of 11, showing that an inhibitor binding 
within the tunnel may not be detected using the bis-pNPP assay. Moreover, selected steroid 
analogues have recently been shown to bind the same site, with the activity of ATX in 
hydrolyzing LPC allosterically inhibited but not its activity on pNP-TMP.29 These reports led us 
to employ the natural substrate 1 in the LPC choline release assay to further evaluate our 
inhibitors, gain a more complete understanding of the underlying SAR, and offer insight into 
potential binding modes. Prior to testing the inhibition of ATX, a control reaction was run using 
three exemplar compounds to ensure that there was no incompatibility with the two coupling 
enzymes used in the assay: choline oxidase and HRP. Using choline chloride as the substrate, no 
inhibition was observed for the latter two reactions of the LPC assay, as shown in Scheme 2 (see 
ESI). Testing proceeded with an initial screen of all 50 compounds from 400 nM Ð 100 µM, to 
identify active inhibitors. From this dataset, compounds that exhibited an IC50 <1 µM were tested 
further across a concentration gradient of 0.3 nM Ð 10 µM, and the IC50 values were determined 
(compounds with IC50 >30 µM not shown, see ESI). This assay provided us with robust 
inhibition data, with the more potent compounds showing full inhibition of ATX. Of the 50 
analogues described in the current study, only four had been previously reported by Amira 
Pharmaceuticals (9, 47, 51, 52).18 The IC50 values determined in our LPC choline release assay 
were consistent with the values claimed in the patents (Table 2). It is also important to note that 
substrate concentration can affect the IC50 value observed in an assay; for competitive assays 
such as bis-pNPP and the LPC choline release assay, the substrate concentration should be less 
than, or equal to, the Michaelis-Menten constant (KM) for the given substrate.
32 The biological 
evaluations detailed in this current study were carried out using substrate concentrations equal to 
the KM values of 1 (~150 µM) and 11 (~1 mM) for ATX previously reported by van Meeteren et 
al.33  
Table 2. Bis-pNPP and LPC assay results. 
Compound 
Bis-pNPP 
IC50 (nM) 
LPC 
IC50 (nM) 
 9 22 ±6.9 4 ±0.5a 
17 604 ±113 25 ±13 
23 - >20 µMb 
24 - >8000b 
28 5700 ±2500 1700 ±400 
29 - 258 ±127 
30 - >3500b 
31 816 ±564 349 ±125 
32 - >10 µMb 
33 85 ±22 25 ±12 
35 75 ±37 124 ±37 
40 >4000b 31 ±11 
41 2000 ±785 >2800b 
42  - - c 
47 100 ±36 1200 ±800d 
49 290 ±35 747 ±500 
50 >4000b  >20 µMb 
51 5 ±2.5 81 ±28a 
52 - 11 ±7a 
56 >30 µM  >5000b 
64 204 ±88  726 ±155 
68 89 ±43 339 ±190 
69 33 ±16 660 ±224 
80 -  >10 µMb 
All tested from 0.3 nM Ð 10 µM, 10 point curves, n = 2. aConsistent with the value of < 300 nM 
claimed in the patent, LPC assay. bIncomplete curve observed. cUnable to determine IC50 due to 
solubility issues in the assay medium. dConsistent with the value of >1 uM claimed in the patent, 
LPC assay.  
Structure-activity Relationship. Using the results from the LPC assay we were able to define 
the SAR around this chemotype and provide a better understanding of the features which 
contribute to its potency. During our examination of the patent data, it became apparent that the 
6-Cl of compound 9 was of high importance to the potency. The deletion analogue 75, in which 
the indole was removed with a phenyl ring used as the core, had resulted in a complete loss of 
activity (data not shown, see ESI), thus confirming the importance of the indole core. To 
investigate the SAR of the 6-Cl substitution on the indole, a series of analogues were made 
varying the position of the chloro around the benzenoid ring, as well as removing the substituent 
(Table 3). We also aimed to explore the significance of the chloro by exchanging this for 
alternative functionalities: F, OMe, and Me. The effect of this chloro on potency was apparent 
throughout our results, with its presence increasing the potency in every example. It was also 
identified that the 6-position of the indole ring was optimal for the chloro, with the other 
regioisomers resulting in lowered or a complete loss of activity (Table 3). This can be noted in 
the comparison of compounds 9, 18, and 29, with the movement of the chloro substituent around 
the indole ring. 
N
S
Me
N
O
OH
R
N
N
Me  
Table 3. SAR of indole ring. 
Compound R IC50 (LPC) 
28 H 1700 ±400 nM 
18 4-Cl >30 µM 
29 5-Cl 258 ±127 nM 
9 6-Cl 4 ±0.5 nM 
30 4-F >3 µMa 
31 6-F 349 ±125 nM 
32 4-Me >10 µMa 
33 6-Me 25 ±12 nM 
34 4-OMe >30 µM 
35 6-OMe 124 ±37 nM 
aIncomplete curve observed. 
 
In order to rationalize the effect of the 6-Cl, docking studies were performed using the apo form 
of the ATX enzyme. From this work it was proposed that the 6-Cl projects into a nearby 
hydrophobic cleft (Leu160, Ala164, Trp207, Trp161), making a series of hydrophobic 
interactions (Figure 11B). The 6-Cl substituent is a vital motif for potency throughout this 
chemotype, therefore we hypothesize that the hydrophobic interactions of this substituent with 
the hydrophobic cleft are key contributors to the potency. It was possible to exchange the 6-Cl 
for alternative substituents (F, 31; Me, 33; OMe, 35) and retain the activity, although the chloro 
was optimal. Based on our in silico model, a conclusion was drawn that the 6-Cl substituent 
provides the optimal size to fit within the hydrophobic pocket with a larger (Me, 33) or smaller 
(F, 31) substituent resulting in a loss of potency. 
   
  
 
Figure 11. In silico studies created using co-crystal of ATX with 2 and 8 PDB 4ZG7. A: Model 
of 51 (yellow) overlayed with cocrystal of 8 (colored by atom type) and ATX, with 2 residing in 
the catalytic site and hydrophobic pocket. B: Model of ATX with 9 highlighting possible 
interactions. C: Shift observed when 4-Cl substituted 18 is docked (yellow) vs. 6-Cl substituted 9 
(colored by atom type). Docked using GOLD30 and viewed using Discovery Studio Visualizer31 
(see ESI). 
 
A B 
Phe157 
C 
Moving these alternative substituents from the 6- to the 4-position of the indole resulted in loss 
of activity, providing further support to the importance of the 6-position. It was noted that with 
no substituent on the indole some weak activity was observed with an IC50 of 1700 nM for 
compound 28; however, introduction of a substituent to the 4-position resulted in loss of activity 
(18, 32, 34), with the exception of the 4-F which is tolerated (30), showing that substitution at 
this position prevents binding of these compounds. Using our in silico model, we suggest that a 
clash between the 4-position substituents and a nearby residue (Phe157) alters the binding of 
these analogues (Figure 11B). This shift in the binding position caused by the clash with the 
protein could explain the loss in potency observed when a substituent is introduced to the 4-
position.  
The next region to be explored was the substitution on the indole nitrogen. In order to establish 
whether the aromatic substituent was required for activity, and if the size of the substituent was 
important, three alternative substituents were used in place of the 1-methyl-pyrazole: methyl, 
cyclopentyl, and phenyl. Analogues with the unsubstituted indole were also synthesized to 
determine whether any substituent at this region was required for activity. Based on the patent 
data, the 1-methyl-pyrazole is important for activity and removal of this substituent did result in 
a reduction in potency; however, compound 17 with no decoration of the indole nitrogen, was a 
potent compound with an IC50 of 25 nM. Further analogues exploring the substitution of the 
indole nitrogen (methyl, cyclopentyl, phenyl) found that the 1-methyl-pyrazole remained the 
most active (Table 4). Unfortunately, we were unable to determine the IC50 of compound 42 due 
to poor solubility in the assay medium observed during the screening of this analogue. Our 
binding model had indicated possible π-π interactions for the 1-methyl-pyrazole of 9 with nearby 
residues (Trp207: pyrazole face to indole edge and Phe221: face to face). By changing the 1-
methyl-pyrazole to an aliphatic substituent these interactions are lost, thus resulting in a loss of 
activity. The methyl group of 40 was well tolerated, whereas the cyclopentyl substituent of 41 
was found to cause a large drop in potency. These results suggest that the larger aliphatic 
substituent is detrimental, either through unfavorable interactions or by clashing with the protein; 
however, we did not observe either from consideration of our binding model.  
 
Table 4. SAR of indole nitrogen substituent, with 6-Cl. 
Compound X R
1
 R
2
 IC50 (LPC) 
9 N Cl 1-methyl-pyrazole 4 ±0.5 nM 
17 N Cl H 25 ±13 nM 
40 N Cl Me 31 ±11 nM 
41 N Cl cyclopentyl >2800 nMb 
42 N Cl Ph - a 
19 N H H >30 µM 
28 N H 1-methyl-pyrazole 
1700 ±400 
nM 
37 N H Me >30 µM 
38 N H cyclopentyl >30 µM 
39 N H Ph >30 µM 
52 CH Cl 1-methyl-pyrazole 11 ±7 nM 
49 CH Cl H 747 ±500 nM 
47 CH Cl Me 
1200 ±800 
nM 
50 CH Cl cyclopentyl >25 µMb 
51 CH Cl Ph 81 ±28 nM 
aUnable to determine due to solubility issues in the assay medium. bIncomplete curve observed. 
 
The relationship between the 1-methyl-pyrazole and the 6-Cl was highlighted by altering the 
substitution of the indole nitrogen in a series of compounds that did not feature the 6-Cl 
substitution. In this series of analogues (Table 4), only one compound exhibited weak activity, 
which was the 1-methyl-pyrazole 28, thus showing that either the 6-Cl or the 1-methyl-pyrazole 
must be present for activity; however, the 6-Cl substituent has the most profound effect on 
activity.  
This series of compounds was explored further via the synthesis of the analogous series with the 
nitrogen removed from the pyridine ring, thus allowing for the SAR of the pyridyl acid and the 
phenyl to be determined. The benzoic acid analogues demonstrated the same SAR as the pyridyl 
sub-series, with the 1-methyl-pyrazole (52) giving the best inhibition (Table 4). Fortunately, 
compound 51 showed good solubility in the assay medium, allowing for the IC50 to be 
determined at 81 nM, unlike the pyridyl analogue 42 with which we had observed poor solubility 
during screening in the LPC assay. This set of analogues additionally supports our observation 
from the data in Table 4; that it is beneficial to have a substituent of aromatic nature on the 
indole nitrogen, and although a cyclopentyl is unfavorable (50), smaller aliphatic groups can be 
tolerated (47). 
The acidic group of this chemotype was also found to be vital for ATX activity, as shown by the 
two deletion analogues in which the thioether linked pyridine was removed (66) or exchanged 
for an aliphatic acid (81) which resulted in loss of activity (Table 5). During our docking studies 
of 9, it was noted that both the indole ring and the 1-methyl-pyrazole substituent could 
potentially contribute to binding through π-π interactions; however, with the pyridyl acid 
orientated towards the solvent it made no specific interactions with ATX, and only a potential H-
bonding interaction with a crystallographic water molecule was identified. The loss of activity 
observed with 66 and 81 could indicate that the aromaticity is required for additional interactions 
not identified in our docking study, or that the increased number of rotatable bonds was 
unfavorable in the binding of this compound within ATX. By comparing the benzoic acid 
compound 52 with the corresponding pyridyl analogue 9 we observed no significant change in 
potency with removal of the pyridyl nitrogen; however, by comparing matched pair examples 
with N-substituents other than the 1-methyl-pyrazole, it can be noted that the pyridine in general 
improves potency (Table 4).  
 Table 5. SAR of the carboxylic acid region. 
Compound R IC50 (LPC) 
9 
 
4 ±0.5 nM 
52 
 
11 ±7 nM 
81 
 
>30 µM 
66 H >30 µM 
 
The thioether linker was then explored through replacement with an ether or a methylene. 
Previous reports from the patent literature had disclosed no analogues with the methylene, and 
only five with an ether linker, thus we sought to fill the SAR gap with a set of analogues using an 
ether and methylene with both the pyridyl and benzoic acids. A large drop in potency was 
observed as a result of changing the thioether (9) to a methylene spacer (68). We also noted this 
trend in the benzoic acid analogues with the thioether (52) being superior to an ether (64) or 
methylene (69) linker, though both alternatives were tolerated (Table 6). Our docking model 
provided little insight into the effects of changing the linker (see ESI); thus we hypothesize that 
the longer bond lengths of the thioether are beneficial to the binding of this chemotype. 
Furthermore, this subset again demonstrates the importance of the 6-Cl for activity and the 
superiority of the pyridyl analogues over the corresponding phenyl analogues. 
N
Y
Me
X
O
OH
N
N
Me
R
 
Table 6. SAR of the linker. 
Compound R Y X IC50 (LPC) 
28 H S N 1700 ±400 nM 
9 Cl S N 4 ±0.5 nM 
53 H S C >30 µM 
52 Cl S C 11 ±7 nM 
62 H O C >30 µM 
64 Cl O C 726 ±155 nM 
71 H CH2 N >30 µM 
68 Cl CH2 N 339 ±190 nM 
70 H CH2 C >30 µM 
69 Cl CH2 C 660 ±224 nM 
 
Mechanistic Studies. To explore the potential binding mode of this chemotype, enzyme kinetic 
studies were carried out in the presence of four representative inhibitors: compound 9, 17, 47, 
and 51. ATX activity for varying substrate concentrations (1) was measured in concentrations of 
each inhibitor. A mixed inhibition mathematical model was fitted to the original data to 
determine the value of alpha; values of alpha close to 1 indicate noncompetitive inhibition.34 To 
graphically demonstrate the inhibition mode, we also present Lineweaver-Burk double reciprocal 
plots (Figure 12). These studies show that as the inhibitor concentration was increased, the Vmax 
reduced but the KM remained unchanged, which is indicative of noncompetitive inhibition. 
Consistently, the values of alpha for each of the compounds ranged between 0.6 and 2.6, 
characteristic of noncompetitive inhibition. Thus, all four exemplar compounds are strongly 
noncompetitive inhibitors. This data, along with the differences observed between the two ATX 
inhibition assays used, suggests that this chemotype has a distinct binding mode, remote to that 
of the catalytic site of ATX, similar to that reported for the three noncompetitive PharmAkea 
compounds.13 
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Figure 12. Enzyme kinetic studies using compounds 9, 28, 47, and 51. Compound 9: α = 0.8.  
 
Compound 28: α = 0.6. Compound 47: α = 2.6. Compound 51: α = 2.2. The data were plotted 
and the best fit values generated using GraphPad Prism 6 from nonlinear regression analysis to 
an equation corresponding to the mixed inhibition model allowing the determination of alpha. 
The constant ÒalphaÓ defines the effect of an inhibitor binding has on the affinity of the enzyme 
for the substrate, a value close to 1 is indicative of noncompetitive inhibition.34 
Crystallographic Data. In order to confirm the binding mode of this chemotype, the co-
crystallization of a number of the inhibitors described herein with ATX was undertaken. 
Unfortunately, efforts to obtain a crystal structure of the most potent inhibitor 9 with ATX were 
unsuccessful; however, the co-crysallization of 51 (IC50 = 81 ±28 nM) with ATX was successful 
and the structure of this complex determined to 2.4  resolution, PDB 5LQQ. After molecular 
replacement and model adjustment difference, electron density in the tunnel close to the 
hydrophobic pocket could be observed, and compound 51 could be modelled in the difference 
density map. The docked position of 51 in our previously described in silico model with ATX 
(Figure 11) was found to be consistent with the binding mode observed in the cocrystal of 51 and 
ATX (Figure 13). 
 
Figure 13. Crystal structure (PDB 5LQQ) vs docking model of 51 with ATX. Cocrystal 
structure of 51 (colored by atom type) overlayed with docking model of 51 (yellow). Docked 
using GOLD30 and viewed using Discovery Studio Visualizer31 (see ESI). 
 
The thioether, indole, and N-phenyl are very clear in the electron map; however, the benzoic acid 
is not well resolved, possibly due to disorder (see ESI for density map). This structure allowed us 
to locate the binding mode of this chemotype and confirm a number of key binding interactions 
(Figure 14). 
 
  
 
Figure 14. Crystallographic data of 51 with ATX. A: 51 bound within the tunnel, remote from 
the catalytic site. B: Stick and ball model of 51. C: Ligand display for interaction and analysis 
(LIDIA) graph of 51. Model and LIDIA graph built using COOT.35 Images created using 
CCP4MG.36 
 
Compound 51 binds in a very similar pose compared to the PharmAkea inhibitor 8 (PDB 
4ZG7),13 which shares a number of structural similarities to analogue 51. The placement of the 
A B C 
thioether and indole moieties is nearly identical in the two structures, while the phenyl of 51 
overlaps well with the cyclopropyl-dihydroindole in 8. The 6-Cl substituent, shown to be vital 
for potency in our SAR studies, resides in a hydrophobic cleft, resulting in a series of 
interactions to nearby residues (Figure 11B). Both the indole ring and the N-phenyl substituent 
contribute to binding with a number of π-π interactions; however, the benzoic acid (51) appears 
to make few discernible interactions with ATX as it is orientated towards the solvent. In the case 
of compound 8, however, the fluoro-benzoic acid makes interactions with the main chain amide 
of Val278, a well-ordered glycerol molecule, and a crystallographic water molecule (see ESI) 
and is thus very well defined in a single conformation in the electron density map. This is in 
sharp contrast to the benzoic acid in 51 that is clearly disordered, which suggests that the fluoro 
substituent of the benzoic acid ring may help to order it in a defined position within the tunnel. 
Alternatively, the presence of the phospholipid (2) in the structure of 8 bound to ATX, but not 
present in our structure with 51, may help order this ring system. Docking studies result in an 
excellent overlay of 51 with 8 as expected, but the benzoic acid moiety was able to rotate around 
the thioether and project in a number of different vectors (see ESI). The disorder observed of the 
benzoic acid in the cocrystal structure of 51 with ATX supports the hypothesis that the thioether 
has rotational freedom. 
Physicochemical Properties. ATX inhibitors that resemble the natural ligand have high 
molecular weight (MW) and high logD resulting in poor drug discovery potential. We were 
interested in the Amira compound 9, not only due to its unique non-lipid chemotype, but also 
because its lower MW and improved lipophilicity it is potentially a more druglike inhibitor. With 
this in mind, we evaluated some key physicochemical properties as well as potency for a selected 
number of the analogues synthesized. Table 7 details the physicochemical properties of the 
analogues in which the indole nitrogen substituent was varied (see ESI for further properties 
measured). Compounds 9, 17, and 40 all showed good ligand efficiency in terms of both ligand 
efficiency index (LEI) and lipophilic ligand efficiency (LLE); however, the introduction of the 
pyrazole in compound 9 improves both potency and LLE.  
 
Table 7. Physicochemical properties of indole nitrogen substituent analogues. 
Compound R MW logD7.4
a
 
Sol.
b 
(µM) 
Papp
c 
(nm s
−1
) 
PSA
d
 IC50
e
 LEI
f
 LLE
9 
1-methyl-
pyrazole 
399 2.70 377 23 76 4 nM 0.31 6 
17 H 319 2.19 ≥395 11 69 25 nM 0.36 5 
40 Me 333 2.68 300 32 58 31 nM 0.34 5 
41 cyclopentyl 386 4.05 336 290 58 >2800 nM 0.21 1 
42 Ph 395 4.30 485 155 58 - h - - 
alogD, Chrom log D at pH 7.4; bChemiluminescent nitrogen detection (CLND) kinetic aqueous solubility assay; cPapp 
permeability pH 7.4 assay;46 dTopological polar surface area (PSA) determined using JChem for Office (Excel) 
16.3.2100.656, 2008-2016, ChemAxon (http://www.chemaxon.com). eIC50 in LPC choline release assay; 
f Ligand 
efficiency index, LEI = pIC50/HA, where HA denotes the number of non-hydrogen atoms; 
gLipophilic ligand 
efficiency, LLE = pIC50 Ð logD. 
hUnable to determine due to solubility issues in the assay medium.  
 
As expected, the compounds with the more lipophilic N-substituents, cyclopentyl (41) and 
phenyl (42), had increased logD7.4, lowered PSA, and increased permeability. All the analogues 
in this series had reasonable aqueous solubility when measured using a high throughput 
screening solubility assay, including compound 42 with which we had observed poor solubility 
in the assay medium. By comparing compounds 9 and 52 we were able to determine the effects 
that the pyridine ring has on the physicochemical properties of this chemotype (Table 8). 
Although the activities and the LEI values of these two analogues are comparable, the lower 
logD7.4 of 9 improves the LLE, giving it an excellent LLE value of 6. At first glance this can 
make 9 appear to be a more attractive molecule; however, the introduction of the pyridine 
increases the PSA and lowers permeability of 9 and thus 52 is perhaps the more attractive 
analogue. In particular, 52 has significantly improved solubility and permeability compared to 
the progenitor pyridine system 9. This is not associated with any significant reduction in potency 
against ATX, as evidenced by the essentially conserved ligand efficiency value. 
 
Table 8. Physicochemical properties of benzoic acid vs. pyridyl. 
Compound X MW logD7.4
a
 
Sol.
b 
(µM) 
Papp
c 
(nm s
−1
) 
PSA
d
 IC50
e
 LEI
f
 LLE
g
 
9 N 399 2.70 377 23 76 4 nM 0.31 6 
52 CH 398 3.36 556 64 63 11 nM 0.30 5 
alogD, Chrom log D at pH 7.4; bChemiluminescent nitrogen detection (CLND) kinetic aqueous solubility assay; cPapp 
permeability pH 7.4 assay;46 dTopological polar surface area (PSA) determined using JChem for Office (Excel) 
16.3.2100.656, 2008-2016, ChemAxon (http://www.chemaxon.com). eIC50 in LPC choline release assay; 
f Ligand 
efficiency index, LEI = pIC50/HA, where HA denotes the number of non-hydrogen atoms; 
gLipophilic ligand 
efficiency, LLE = pIC50 Ð logD.  
 
CONCLUSION 
We designed and synthesized a series of analogues to explore the atypical ATX inhibitor 9, 
previously reported by Amira Pharmaceuticals. In the current study, we have developed a robust 
SAR through the biological assessment of our compound library using two different ATX 
assays. This survey has established that some compounds inhibit hydrolysis of the natural 
substrate (LPC) but only partially inhibit activity with an artificial substrate. Based on this we 
can infer a binding mode outside of the orthosteric site and this was corroborated by kinetic 
studies, which identified this chemotype as a noncompetitive ATX inhibitor. In addition to this, a 
crystal structure of ATX bound to compound 51 confirmed that it binds within the tunnel, which 
is an underexploited and recently described allosteric binding site. We emphasize that cross 
screening with an assay using a natural substrate is important to determine the true inhibitory 
activity of compounds for this enzyme. Through the measurement of the physicochemical 
properties, we demonstrated that this chemotype had consistently good aqueous solubility, with 
the more potent analogues possessing excellent LLE. This combined biochemical, biostructural, 
and physicochemical work has provided a more detailed insight into the SAR and binding mode 
of these small molecule ATX inhibitors, which could aid the design of new novel ATX inhibitors 
with non-lipid-like scaffolds. 
 
EXPERIMENTAL SECTION 
General Procedures. All reagents and solvents were obtained from commercial suppliers and 
were used without further purification unless otherwise stated. Purification was carried out 
according to standard laboratory methods.37 All solvents for dry reactions were distilled 
according to standard laboratory practice. These solvents were transferred to a septum-sealed 
oven-dried flask over previously activated 4  molecular sieves and purged with and stored 
under nitrogen. Dichloromethane, ethyl acetate, methanol, petroleum ether 40-60o, and 
cyclohexane for purification purposes were used as obtained from suppliers without further 
purification. Thin layer chromatography (TLC) was carried out using Merck silica plates coated 
with fluorescent indicator UV254. These were analyzed under 254 nm UV light or developed 
using potassium permanganate solution. Silica chromatography was carried out using ZEOprep 
60 HYD 40-63 µm silica gel or IST Isolute Flash silica cartridges. Reverse-phase HPLC 
purification was carried out using a Gilson 151 preparative HPLC using an Agilent Zorbax SB-
C18 column at room temperature. Purification was performed using a gradient method, eluting 
with 5-80% acetonitrile/water over 15 minutes at a flow rate of 10 mL/min. Fractions were 
collected automatically using a GX-271 liquid handler. Reverse-phase ultra-performance liquid 
chromatography (UPLC) purification was carried out using an Acquity UPLC CSH C18 column 
at 40 ¡C. Purification was performed using a gradient method, eluting with 5-97% acetonitrile/10 
mM (NH4)HCO3 in water. Mass-directed automatic purification (MDAP) was carried out using a 
ZQ MS using alternate-scan positive and negative electrospray and a summed UV wavelength of 
210-350 nm and an Xbridge C18 column (100 mm x 19 mm, 5 µm packing diameter, 20 mL/min 
flow rate) or Xbridge C18 column (150 mm x 30 mm, 5 µm packing diameter, 40 mL/min flow 
rate). Purification was performed using a gradient method at room temperature with the mobile 
phases as (A) 10 mM aqueous ammonium bicarbonate solution, adjusted to pH 10 with 0.88 M 
aqueous ammonia and (B) acetonitrile. All compounds for testing were purified to at least 95% 
purity, as verified by HPLC, 1H NMR, and high-resolution mass spectrometry (HRMS). Fourier 
Transformed Infra-Red (FTIR) spectra were obtained on one of three machines: (i) Shimadzu 
IRAffinity-1 machine; (ii) A2 Technologies ATR spectrometer; (iii) Agilent 5500a FTIR ATR. 
1H, 13C, and 19F NMR spectra were obtained on a one of four Bruker NMR spectrometers: (i) 
Advance III HD console, Ascend 500 MHz magnet, BBO smart probe; (ii) Advance III console, 
400 MHz Ultrashield magnet, Prodigy BBO probe, BB-H&F-D-05 Z; (iii) Advance II console, 
400 MHz 9.4 T Oxford unshielded magnet, BBFO-z-ATMA probe; (iv) Advance III console, 
600 MHz 14.1 T Bruker Ultrashield magnet, TBI-z probe. Chemical shifts are reported in ppm 
and coupling constants are reported in Hz with CDCl3 referenced at 7.26 (
1H) and 77.16 ppm 
(13C), CO(CD3)2 at 2.05 (
1H) and 29.84 ppm (13C), MeOD at 3.31 (1H) and 49.00 ppm (13C), and 
DMSO-d6 at 2.50 (
1H) and 39.52 ppm (13C), respectively. HRMS were obtained through analysis 
at the EPSRC National Mass Spectrometry Facility, University of Wales, Swansea or on a 
Micromass Q-Tof Ultima hybrid quadrupole time-of-flight mass spectrometer, with analytes 
separated on an Agilent 1100 Liquid Chromatograph equipped with a Phenomenex Luna C18(2) 
reversed phase column (100 mm x 2.1 mm, 3 µm packing diameter). LC conditions were 0.5 
mL/min flow rate, 35 ¼C, injection volume 2-5 µL. Gradient elution with (A) water containing 
0.1% (v/v) formic acid and (B) acetonitrile containing 0.1% (v/v) formic acid. Gradient 
conditions were initially 5% B, increasing linearly to 100% B over 6 min, remaining at 100% B 
for 2.5 min then decreasing linearly to 5% B over 1 min followed by an equilibration period of 
2.5 min prior to the next injection. 
Materials. Ethyl 6-((2-oxopropyl)thio)picolinate (13) was obtained from GVK Biosciences 
Private Limited (ref. 25). Bromocyclopentane was distilled over anhydrous calcium carbonate 
under reduced pressure prior to use.  
General Procedure 1: Fischer Indole synthesis. For example, ethyl 6-((6-chloro-2-methyl-
1H-indol-3-yl)thio)picolinate (16). Prepared according to a modified version of the procedure 
described by Amira Pharmaceuticals.18 To a round bottomed flask ethyl 6-((2-
oxopropyl)thio)picolinate (13) (512 mg, 2.09 mmol, 1 equiv.) and (3-chlorophenyl)hydrazine 
hydrochloride (374 mg, 2.09 mmol, 1 equiv.) were added and dissolved in tBuOH (25 mL, 0.08 
M) and stirred at 80 ¡C for 16 h. Following this, 1 M HCl in Et2O (0.3 mL) was added to the 
reaction mixture and stirred for a further 2 h before adding AcOH (0.3 mL) and stirred for a 
further 1 h. The reaction mixture was then allowed to return to room temperature and 
concentrated under vacuum to a residue that was purified by reverse-phase UPLC to afford the 
title compound as a brown solid (517 mg, 71%). 
General Procedure 2: Ullmann coupling. For example, 6-((6-chloro-2-methyl-1-(1-methyl-
1H-pyrazol-4-yl)-1H-indol-3-yl)thio) picolinic acid (9). Prepared according to a modified 
version of a literature procedure for an Ullmann coupling.38 To a microwave vial was added 
1,10-phenanthroline (56 mg, 0.311 mmol, 1 equiv.), CuI (30 mg, 0.156 mmol, 0.5 equiv.), 
Cs2CO3 (203 mg, 0.622 mmol, 2 equiv.), 4-iodo-1-methyl-1H-pyrazole (129 mg, 0.622 mmol, 2 
equiv.), and ethyl 6-((6-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (16) (108 mg, 0.311 
mmol, 1 equiv.). The reaction vessel was then sealed and purged with N2 before addition of 
DMF (1 mL, 0.3 M). The reaction was then heated to 110 ¡C for 48 h. The reaction mixture was 
then diluted with water (15 mL) and extracted with EtOAc (3 x 10 mL). The combined organics 
were dried (hydrophobic frit), and concentrated under vacuum to a residue that was purified 
using MDAP to afford the title compound as a pale yellow solid (10 mg, 8%). 
General Procedure 3: Ester hydrolysis. For example, 6-((2-methyl-1H-indol-3-
yl)thio)picolinic acid (19). To a round bottomed flask was added a solution of ethyl 6-((2-
methyl-1H-indol-3-yl)thio)picolinate (36) (56 mg, 0.179 mmol, 1 equiv.) and 2 M aq. NaOH (0.5 
mL) in THF (0.5 mL, 0.4 M) and the reaction stirred at room temperature until complete by 
TLC. The reaction mixture was then concentrated under vacuum to a residue that was purified 
using MDAP to afford the title compound as a brown amorphous solid (27 mg, 53%). 
General Procedure 4: N-Arylation. For example, 6-((2-methyl-1-(1-methyl-1H-pyrazol-4-
yl)-1H-indol-3-yl)thio)picolinic acid (28). Prepared according to a modified version of the 
procedure described by Amira Pharmaceuticals.18 To a microwave vial was added ethyl 6-((2-
methyl-1H-indol-3-yl)thio)picolinate (36) (198 mg, 0.635 mmol, 1 equiv.), 4-bromo-1-methyl-
1H-pyrazole (198 µL, 1.90 mmol, 3 equiv.), K2CO3 (114 mg, 0.826 mmol, 1.3 equiv.), and CuO 
(102 mg, 1.27 mmol, 2 equiv.). The vial was then sealed and purged with N2 before the addition 
of pyridine (2 mL, 0.3 M). The reaction mixture was then heated to 170 ¡C for 16 h. The reaction 
mixture was then allowed to return to room temperature, diluted with EtOAc (15 mL), and 
washed with water (3 x 10 mL). The organic layer was collected, dried (hydrophobic frit), 
concentrated under vacuum, and the residue purified using reverse-phase HPLC to afford the 
title compound as a yellow amorphous solid (15 mg, 6%). 
General Procedure 5: Alternative Fischer Indole synthesis. For example, ethyl 6-((5-chloro-
2-methyl-1H-indol-3-yl)thio)picolinate (82). A solution of ethyl 6-((2-
oxopropyl)thio)picolinate (13) (1 g, 4.18 mmol, 1 equiv.) and (4-chlorophenyl)hydrazine 
hydrochloride (749 mg, 4.18 mmol, 1 equiv.) in EtOH (25 mL, 0.2 M) was refluxed until the 
reaction was complete by TLC. The reaction mixture was then allowed to return to room 
temperature, concentrated under vacuum, and the residue purified using silica chromatography, 
eluting with 0-50% EtOAc/cyclohexane, to afford the title compound as a brown amorphous 
solid (460 mg, 32%).  
General Procedure 6: N-Alkylation of the indole. For example, methyl 3-((1,2-dimethyl-1H-
indol-3-yl)thio)benzoate (93). A solution of methyl 3-((2-methyl-1H-indol-3-yl)thio)benzoate 
(92) (200 mg, 0.673 mmol, 1 equiv.), and NaH 60% w/w (54 mg, 1.35 mmol, 2 equiv.) in THF 
(3 mL, 0.2 M) was heated to 60 ¡C for 1 h before adding MeI (84 µL, 1.35 mmol, 2 equiv.). The 
reaction mixture was heated to 60 ¡C for 16 h then allowed to return to room temperature, 
concentrated under vacuum, and the residue purified using silica chromatography, eluting with 
10% EtOAc/petroleum ether, to afford the title compound as a pale yellow amorphous solid (71 
mg, 34%). 
General Procedure 7: Methoxycarbonylation. For example, methyl 3-((2-methyl-1H-indol-
3-yl)thio)benzoate (92). trans-Bis(acetato)bis[o-(di-o-tolylphosphino)benzyl] dipalladium(II) 
(184 mg, 0.196 mmol, 5 mol%) was added to a solution of 3-((3-bromophenyl)thio)-2-methyl-
1H-indole (91) (1.24 g, 3.91 mmol, 1 equiv.), Mo(CO)6 (1 g, 3.91 mmol, 1 equiv.), [tBu3PH]BF4 
(227 mg, 0.782 mmol, 20 mol%), and DBU (875 µL, 5.86 mmol, 1.5 equiv.) in MeCN/MeOH 
(20 mL, 1:4, 0.2 M). The reaction mixture was heated to 70 ¡C for 16 h then allowed to return to 
room temperature, concentrated under vacuum, and the residue purified using silica 
chromatography, eluting with 20% EtOAc/petroleum ether, to afford the title compound as a 
brown solid (1 g, 88%). 
General Procedure 8: Two-step alkylation. For example, 3-(3-bromobenzyl)-6-chloro-2-
methyl-1H-indole (101). 6-Bromopyridine-2-carbaldehyde (91 mg, 0.488 mmol, 1.03 equiv.) 
was added to a solution of 2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (98) (100 mg, 
0.474 mmol, 1 equiv.) in CH2Cl2 (2 mL, 0.2 M) at 0 ¡C and stirred for 20 min. Et3SiH (84 µL, 
0.529 mmol, 1.1 equiv.) and TFA (47 µL, 0.610 mmol, 1.3 equiv.) were then added to the 
reaction mixture and stirred for a further 1 h, during which the reaction mixture was allowed to 
return to room temperature. The resulting solution was then quenched with sat. aq. NaHCO3 and 
extracted using CH2Cl2 (20 mL). The organic layer was collected, dried (hydrophobic frit), 
concentrated under vacuum, and the residue purified using silica chromatography, eluting with 
20-60% EtOAc/petroleum ether, to afford the title compound as a yellow gum (158 mg, 87%). 
6-((6-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio) picolinic acid (9). 
Prepared according to General Procedure 2 using 1,10-phenanthroline (56 mg, 0.311 mmol, 1 
equiv.), CuI (30 mg, 0.156 mmol, 0.5 equiv.), Cs2CO3 (203 mg, 0.622 mmol, 2 equiv.), 4-iodo-1-
methyl-1H-pyrazole (129 mg, 0.622 mmol, 2 equiv.), and ethyl 6-((6-chloro-2-methyl-1H-indol-
3-yl)thio)picolinate (16) (108 mg, 0.311 mmol, 1 equiv.) in DMF (1 mL, 0.3 M). Purified using 
MDAP to afford the title compound as a pale yellow solid (10 mg, 8%). 1H NMR (400 MHz, 
MeOD) δ 8.06 (s, 1H), 7.90 Ð 7.79 (m, 1H), 7.78 (s, 1H), 7.73 Ð 7.61 (m, 1H), 7.46 (d, J = 8.3 
Hz, 1H), 7.23 (d, J = 1.7 Hz, 1H), 7.16 (d, J = 7.1 Hz, 1H), 6.97 Ð 6.84 (m, 1H), 4.07 (s, 3H), 
2.43 (s, 3H). CO2H proton not observed. 
13C NMR (126 MHz, CDCl3): δ 163.7, 161.5, 145.9, 
144.9, 139.1, 138.6, 129.0, 127.9, 127.6, 127.5, 126.8, 124.0, 122.3, 119.4, 110.7, 97.8, 39.9, 
11.6. One carbon not observed/coincident. υmax (neat): 2947, 2924, 1712, 1577 cm
-1. HRMS: 
exact mass calculated for [M+H]+ (C19H16ClN4O2S) m/z requires 401.0646, m/z found 401.0646.  
Ethyl 6-((4-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (14). Prepared according to General 
Procedure 1 using ethyl 6-((2-oxopropyl)thio)picolinate (13) (512 mg, 2.09 mmol, 1 equiv.) and 
(3-chlorophenyl)hydrazine hydrochloride (374 mg, 2.09 mmol, 1 equiv.) in tBuOH (25 mL, 0.1 
M) with additional 1 M HCl in Et2O (0.3 mL) and AcOH (0.3 mL). Purified using reverse-phase 
UPLC to afford ethyl 6-((4-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (14) as a white 
amorphous solid (125 mg, 17%). Ethyl 6-((4-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (14): 
1H NMR (600 MHz, MeOD): δ 7.75-7.71 (m, 1H), 7.58 (app t, J = 7.9 Hz, 1H), 7.33 (dd, J = 8.0, 
0.5 Hz, 1H), 7.07 (app t, J = 7.9 Hz, 1H), 7.00 (dd, J = 7.6, 0.5 Hz, 1H), 6.82 (dd, J = 8.2, 0.6 
Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 2.49 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H). NH proton not observed. 
13C NMR (151 MHz, MeOD): δ 165.8, 164.8, 147.2, 144.1, 137.7, 137.5, 125.4, 124.8, 122.7, 
122.0, 121.2, 120.0, 109.9, 95.2, 61.6, 13.1, 10.4. υmax (neat): 3267, 2980, 1720, 1572, 1537 cm
-
1. HRMS: exact mass calculated for [M+H]+ (C17H16ClN2O2S) m/z requires 349.0585, m/z found 
349.05885.  
6-((4-Chloro-2-methyl-1H-indol-3-yl)thio)picolinic acid (15). Prepared according to General 
Procedure 3 using ethyl 6-((4-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (14) (50 mg, 0.144 
mmol, 1 equiv.) and 2 M aq. NaOH (1 mL) in THF (1 mL, 0.1 M). Purified using MDAP to 
afford the desired product as a brown amorphous solid (40 mg, 87%). 1H NMR (400 MHz, 
MeOD): 7.78 (d, J = 7.6 Hz, 1H), 7.63 (app t, J = 7.9 Hz, 1H), 7.36 (dd, J = 7.9, 0.7 Hz, 1H), 
7.10 (app t, J = 7.8 Hz, 1H), 7.03 (d, J = 7.6 Hz, 1H), 6.85 (dd, J = 8.1, 0.7 Hz, 1H), 2.51 (s, 3H). 
NH and CO2H protons not observed.
 13C NMR (101 MHz, MeOD): δ 166.0, 165.5, 147.1, 144.1, 
137.7, 125.4, 124.8, 122.8, 122.0, 121.2, 119.9, 109.9, 95.1, 10.4. One carbon not 
observed/coincident. υmax (neat): 3250, 3020, 2924, 1708, 1573, 1558, 1535 cm
-1 HRMS: exact 
mass calculated for [M+H]+ (C15H12ClN2O2S) m/z requires 319.0303, m/z found 319.0300. 
Ethyl 6-((6-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (16). Prepared according to General 
Procedure 1 using ethyl 6-((2-oxopropyl)thio)picolinate (13) (512 mg, 2.09 mmol, 1 equiv.) and 
(3-chlorophenyl)hydrazine hydrochloride (374 mg, 2.09 mmol, 1 equiv.) in tBuOH (25 mL, 0.1 
M) with additional 1 M HCl in Et2O (0.3 mL) and AcOH (0.3 mL). Purified using reverse-phase 
UPLC to afford ethyl 6-((6-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (16) as a brown 
amorphous solid (517 mg, 71%). 1H NMR (600 MHz, MeOD): δ 7.73 (dd, J = 7.6, 0.8 Hz, 1H), 
7.59-7.54 (m, 1H), 7.39 (d, J = 1.8 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.02 (dd, J = 8.4, 1.8 Hz, 
1H), 6.74 (dd, J = 8.2, 0.8 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 2.48 (s, 3H), 1.41 (t, J = 7.1 Hz, 
3H). NH proton not observed. 13C NMR (151 MHz, MeOD): δ 164.7, 163.9, 147.5, 143.3, 137.7, 
136. 6, 128.3, 127.4, 122.4, 120.5, 120.3, 118.5, 110.8, 95.9, 61.6, 13.1, 10.4. υmax (neat): 3250, 
2975, 1720, 1574 cm-1. HRMS: exact mass calculated for [M+H]+ (C17H16ClN2O2S) m/z requires 
349.0585, m/z found 349.0587. 
6-((6-Chloro-2-methyl-1H-indol-3-yl)thio)picolinic acid (17). Prepared according to General 
Procedure 3 using ethyl 6-((6-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (16) (100 mg, 0.289 
mmol, 1 equiv.) and 2 M aq. NaOH (1 mL) in THF (1 mL, 0.3 M). Purified using MDAP to 
afford the desired product as a yellow amorphous solid (79 mg, 86%). 1H NMR (400 MHz, 
MeOD): δ 7.77 (dd, J = 7.6, 0.8 Hz, 1H), 7.58 (app t, J = 7.9 Hz, 1H), 7.40 (d, J = 1.9 Hz, 1H), 
7.33 (d, J = 8.4 Hz, 1H), 7.04 (dd, J = 8.4, 1.8 Hz, 1H), 6.74 (dd, J = 8.1, 0.8 Hz, 1H), 2.49 (s, 
3H). CO2H and NH protons not observed 
13C NMR (101 MHz, MeOD): δ 165.9, 163.6, 147.5, 
143.3, 137.8, 136.5, 128.3, 127.4, 122.4, 120.5, 120.2, 118.5, 110.8, 95.9, 10.4. υmax (neat): 
3302, 1734, 1685 cm-1. HRMS: exact mass calculated for [M+H]+ (C15H12ClN2O2S) m/z requires 
319.0303, m/z found 319.0307. 
6-((4-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)picolinic acid (18). 
Prepared according to General Procedure 2 using 1,10-phenanthroline (54 mg, 0.300 mmol, 1 
equiv.), CuI (28 mg, 0.150 mmol, 0.5 equiv.), Cs2CO3 (196 mg, 0.600 mmol, 2 equiv.), 4-iodo-1-
methyl-1H-pyrazole (125 mg, 0.600 mmol, 2 equiv.), and ethyl 6-((7-chloro-2-methyl-1H-indol-
3-yl)thio)picolinate (83) (104 mg, 0.300 mmol, 1 equiv.) in DMF (1 mL, 0.3 M). Purified using 
MDAP to afford the desired product as an off white solid (32 mg, 27%). 1H NMR (600 MHz, 
CDCl3): δ 7.84 (d, J = 7.5 Hz, 1H), 7.65-7.61 (m, 3H), 7.19-7.03 (m, 4H), 4.04 (s, 3H), 2.37 (s, 
3H). CO2H proton not observed.
 13C NMR (151 MHz, MeOD): δ 160.1, 159.2, 142.0, 141.8, 
136.2, 134.4, 133.2, 123.8, 121.7, 121.2, 120.6, 119.1, 119.0, 115.2, 115.0, 105.5, 93.2, 35.9, 
7.7. υmax (neat):1735, 1510, 1500 cm
-1. HRMS: exact mass calculated for [M+H]+ 
(C19H16ClN4O2S) m/z requires 399.0677, m/z found 399.0680. 
6-((2-Methyl-1H-indol-3-yl)thio)picolinic acid (19). Prepared according to General Procedure 
3 using ethyl 6-((2-methyl-1H-indol-3-yl)thio)picolinate (36) (56 mg, 0.179 mmol, 1equiv.) and 
2 M aq. NaOH (0.5 mL) in THF (0.5 mL, 0.4 M). Purified using MDAP to afford the title 
compound as a brown amorphous solid (27 mg, 53%). 1H NMR (400 MHz, MeOD): δ 7.75 (dd, 
J = 7.6, 0.8 Hz, 1H), 7.56 (app t, J = 7.9 Hz, 1H), 7.42-7.34 (m, 2H), 7.18-7.10 (m, 1H), 7.10-
7.01 (m, 1H), 6.75 (dd, J = 8.1, 0.8 Hz, 1H), 2.49 (s, 3H). NH and CO2H protons not observed.
 
13C NMR (101 MHz, MeOD): δ 166.2, 164.1, 163.2, 147.6, 142.1, 137.6, 136.2, 129.6, 122.4, 
121.6, 120.0, 117.4, 110.9, 95.4, 10.4. υmax (neat): 3281, 1749, 1716, 1575, 1558 cm
-1. HRMS: 
exact mass calculated for [M+H]+ (C15H13N2O2S) m/z requires 285.0692, m/z found 285.0693. 
6-((5-Chloro-2-methyl-1H-indol-3-yl)thio)picolinic acid (20). Prepared according to General 
Procedure 3 using ethyl 6-((5-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (82) (46 mg, 0.133 
mmol, 1 equiv.) and 2 M aq. NaOH (0.5 mL) in THF (0.5 mL, 0.3 M). Purified using reverse-
phase HPLC to afford the title compound as a pale brown amorphous solid (37 mg, 87%). 1H 
NMR (400 MHz, MeOD): δ 7.79 (dd, J = 7.6, 0.8 Hz, 1H), 7.63-7.58 (m, 1H), 7.37 (d, J = 8.6 
Hz, 1H), 7.35 (d, J = 1.9 Hz, 1H), 7.13 (dd, J = 8.6, 2.0 Hz, 1H), 6.77 (dd, J = 8.2, 0.8 Hz, 1H), 
2.51 (s, 3H). NH and CO2H protons not observed. 
13C NMR (151 MHz, MeOD): δ 166.0, 163.6, 
147.7, 144.1, 137.8, 134.6, 130.9, 126.0, 122.3, 121.8, 120.2, 116.8, 112.2, 95.4, 10.4. υmax 
(neat): 3304, 2960, 2975 1751, 1705, 1656, 1577 cm-1. HRMS: exact mass calculated for [M+H]+ 
(C15H12ClN2O2S) m/z requires 319.0303, m/z found 319.0307. 
6-((7-Chloro-2-methyl-1H-indol-3-yl)thio)picolinic acid (21). Prepared according to General 
Procedure 5 using ethyl 6-((2-oxopropyl)thio)picolinate (13) (1 g, 4.18 mmol, 1 equiv.) and (2-
chlorophenyl)hydrazine hydrochloride (748 mg, 4.18 mmol, 1 equiv.) in EtOH (25 mL, 0.2 M). 
Following aqueous work-up, the reaction mixture was then used in the next step without further 
purification. The crude material was used according to General Procedure 3 using 2 M aq. NaOH 
(6 mL) in THF (6 mL, 0.7 M). Purified using MDAP to afford the title compound as a pale 
yellow amorphous solid (289 mg, 22% over 2 steps). 1H NMR (600 MHz, MeOD): δ 7.63 (dd, J 
= 7.5, 0.7 Hz, 1H), 7.47 (app t, J = 7.8 Hz, 1H), 7.38 (dd, J = 7.9, 0.7 Hz, 1H), 7.18 (dd, J = 7.6, 
0.7 Hz, 1H), 7.05 (app t, J = 7.8 Hz, 1H), 6.56 (dd, J = 8.1, 0.7 Hz, 1H), 2.56 (s, 3H). NH and 
CO2H protons not observed.
 13C NMR (151 MHz, MeOD): δ 171.4, 162.1, 154.9, 143.4, 137.0, 
133.1, 131.6, 121.0, 120.7, 119.6, 119.0, 116.5, 116.2, 97.8, 10.3. υmax (neat): 3130, 1591, 1556 
cm-1. HRMS: exact mass calculated for [M+H]+ (C15H12ClN2O2S) m/z requires 319.0303, m/z 
found 319.0306. 
6-((4-Fluoro-2-methyl-1H-indol-3-yl)thio)picolinic acid (22). Prepared according to General 
Procedure 3 using ethyl 6-((4-fluoro-2-methyl-1H-indol-3-yl)thio)picolinate (85) (51 mg, 0.154 
mmol, 1 equiv.) and 2 M aq. NaOH solution (0.5 mL) in THF (0.5 mL, 0.3 M). Purified using 
MDAP to afford the title compound as a yellow amorphous solid (46 mg, 99%). 1H NMR (600 
MHz, MeOD): δ 7.75 (dd, J = 7.5, 0.7 Hz, 1H), 7.58 (app t, J = 7.9 Hz, 1H), 7.18 (d, J = 8.2 Hz, 
1H), 7.07-7.03 (m, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.68 (dd, J = 11.1, 7.9 Hz, 1H), 2.46 (s, 3H). 
NH and CO2H protons not observed.
 13C NMR (151 MHz, MeOD): δ 166.1, 164.7, 155.9 (d, 1JC-
F = 246.5 Hz), 147.3, 142.8, 139.0 (d, 
3
JC-F = 10.3 Hz), 137.7, 122.5, 121.9 (d, 
3
JC-F = 7.7 Hz), 
120.0, 117.7 (d, 2JC-F = 17.3 Hz), 107.2 (d, JC-F = 3.8 Hz), 105.3 (d, 
2
JC-F = 19.2 Hz), 93.2 (d, JC-F 
= 1.6 Hz), 10.1. 19F NMR (376 MHz, MeOD): δ -129.6. υmax (neat): 3300, 2600, 1687, 1573 cm
-
1. HRMS: exact mass calculated for [M+H]+ (C15H12FN2O2S) requires m/z 303.0598, found m/z 
303.0596. 
6-((6-Fluoro-2-methyl-1H-indol-3-yl)thio)picolinic acid (23). Prepared according to General 
Procedure 3 using ethyl 6-((6-fluoro-2-methyl-1H-indol-3-yl)thio)picolinate (84) (50 mg, 0.152 
mmol, 1 equiv.) and 2 M aq. NaOH (0.5 mL) in THF (0.5 mL, 0.3 M). Purified using MDAP to 
afford the title compound as a brown amorphous solid (3 mg, 6%). 1H NMR (400 MHz, MeOD): 
δ 7.62 (d, J = 7.5 Hz, 1H), 7.46 (app t, J = 7.8 Hz, 1H), 7.33 (dd, J = 8.6, 5.3 Hz, 1H), 7.09 (dd, J 
= 9.6, 2.2 Hz, 1H), 6.85-6.79 (m, 1H), 6.57 (d, J = 8.0 Hz, 1H), 2.46 (s, 3H). NH and CO2H 
protons not observed. 13C NMR (101 MHz, MeOD): δ 169.1, 163.0, 160.0 (d, 1JC-F = 235.9 Hz), 
151.6, 142.7 (d, JC-F = 0.4 Hz), 137.3, 136.1 (d, 
3
JC-F = 12.6 Hz), 126.1, 120.9, 119.5, 118.4 (d, 
3
JC-F = 10 Hz), 108.1 (d, 
2
JC-F = 24.7 Hz), 97.2 (d, 
2
JC-F = 26.4 Hz), 96.1, 10.4. 
19F NMR (376 
MHz, MeOD): δ -123.86. υmax (neat): 3338, 1732, 1608, 1583, 1556 cm
-1. HRMS: exact mass 
calculated for [M+H]+ (C15H12FN2O2S) requires m/z 303.0598, found m/z 303.0596. 
6-((2,4-Dimethyl-1H-indol-3-yl)thio)picolinic acid (24) and 6-((2,4-dimethyl-1-(1-methyl-
1H-pyrazol-4-yl)-1H-indol-3-yl)thio)picolinic acid (32). Prepared according to General 
Procedure 2 using 1,10-phenanthroline (49 mg, 0.270 mmol, 1 equiv.), CuI (26 mg, 0.135 mmol, 
0.5 equiv.), Cs2CO3 (176 mg, 0.540 mmol, 2 equiv.), 4-iodo-1-methyl-1H-pyrazole (112 mg, 
0.540 mmol, 2 equiv.), and ethyl 6-((2,4-dimethyl-1H-indol-3-yl)thio)picolinate (87) (88 mg, 
0.270 mmol, 1 equiv.) in DMF (1 mL, 0.3 M). Purified using MDAP to afford the desired 6-
((2,4-dimethyl-1H-indol-3-yl)thio)picolinic acid (24) as a an off white amorphous solid (31 mg, 
38%) and 6-((2,4-dimethyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)picolinic acid (32) 
as a white solid (24 mg, 24%). 6-((2,4-Dimethyl-1H-indol-3-yl)thio)picolinic acid (24): 1H NMR 
(400 MHz, MeOD): δ 7.76 (dd, J = 7.6, 0.9 Hz, 1H), 7.63-7.55 (m, 1H), 7.23 (d, J = 8.1 Hz, 1H), 
7.05-6.97 (m, 1H), 6.84-6.75 (m, 2H), 2.56 (s, 3H), 2.47 (s, 3H). NH and CO2H protons not 
observed. 13C NMR (101 MHz, MeOD): δ 166.1, 165.9, 147.4, 142.3, 137.8, 136.4, 129.5, 127.1, 
122.5, 121.8, 121.4, 119.9, 108.9, 95.2, 17.5, 10.3. υmax (neat): 3302, 1690, 1580, 1558 cm
-1. 
HRMS: exact mass calculated for [M+H]+ (C16H15N2O2S) requires m/z 299.0849, found m/z 
299.0849. 6-((2,4-Dimethyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)picolinic acid 
(32): 1H NMR (600 MHz, DMSO-d6): δ 7.16 (s, 1H), 6.94 (d, J = 7.5 Hz, 1H), 6.88 (s, 1H), 6.80 
(app t, J = 7.8 Hz, 1H), 6.30-6.18 (m, 2H), 6.13-5.98 (m, 2H), 4.01 (s, 3H), 1.78 (s, 3H), 1.56 (s, 
3H). CO2H proton not observed.
 13C NMR (151 MHz, DMSO-d6): δ 166.8, 163.9, 148.9, 143.5, 
138.3, 137.0, 135.8, 129.2, 127.9, 125.7, 122.1, 121.3, 121.0, 119.0, 118.6, 107.3, 96.8, 37.5, 
16.8, 9.2. υmax (neat): 2943, 2921, 1720, 1686, 1619, 1574, 1561 cm
-1. HRMS: exact mass 
calculated for [M+H]+ (C20H19N4O2S) requires m/z 379.1223, found m/z 379.1220. 
6-((2,6-Dimethyl-1H-indol-3-yl)thio)picolinic acid (25). Prepared according to General 
Procedure 2 using 1,10-phenanthroline (49 mg, 0.270 mmol, 1 equiv.), CuI (26 mg, 0.135 mmol, 
0.5 equiv.), Cs2CO3 (176 mg, 0.540 mmol, 2 equiv.), 4-iodo-1-methyl-1H-pyrazole (112 mg, 
0.540 mmol, 2 equiv.), and ethyl 6-((2,6-dimethyl-1H-indol-3-yl)thio)picolinate (86) (88 mg, 
0.270 mmol, 1 equiv.) in DMF (1 mL, 0.3 M). Purified using MDAP to afford 6-((2,6-dimethyl-
1H-indol-3-yl)thio)picolinic acid (25) as a yellow amorphous solid (8 mg, 10%): 1H NMR (400 
MHz, MeOD): δ 7.64 (d, J = 7.5 Hz, 1H), 7.46 (app t, J = 7.8 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 
7.18 (d, J = 0.5 Hz, 1H), 6.88 (dd, J = 8.0, 0.9 Hz, 1H), 6.63 (d, J = 8.0 Hz, 1H), 2.45 (s, 3H), 
2.42 (s, 3H). NH and CO2H not observed.
 13C NMR (101 MHz, MeOD): δ 169.2, 163.5, 151.7, 
141.2, 137.1, 136.6, 131.4, 127.5, 121.5, 120.9, 119.2, 117.2, 110.8, 95.6, 20.3, 10.3. υmax (neat): 
3280, 3249, 2900, 1722, 1578, 1560, 1441 cm-1. HRMS: exact mass calculated for [M+H]+ 
(C16H15N2O2S) requires m/z 299.0849, found m/z 299.0849.  
6-((4-Methoxy-2-methyl-1H-indol-3-yl)thio)picolinic acid (26). Prepared according to General 
Procedure 3 using ethyl 6-((4-methoxy-2-methyl-1H-indol-3-yl)thio)picolinate (89) (47 mg 
0.137 mmol, 1 equiv.) and 2 M aq. NaOH (0.5 mL) in THF (0.5 mL, 0.3 M). Purified using 
MDAP to afford the title compound as a yellow amorphous solid (42 mg, 98%). 1H NMR (400 
MHz, MeOD): δ 7.72 (d, J = 7.5 Hz, 1H), 7.55 (app t, J = 7.9 Hz, 1H), 7.06-6.93 (m, 2H), 6.89 
(d, J = 8.2 Hz, 1H), 6.49 (d, J = 7.5 Hz, 1H), 3.59 (s, 3H), 2.43 (s, 3H). NH and CO2H protons 
not observed. 13C NMR (101 MHz, MeOD): δ 165.9, 165.8, 153.5, 146.7, 140.7, 137.8, 137.5, 
123.1, 122.4, 119.7, 118.6, 104.4, 101.0, 94.2, 54.4, 10.2. υmax (neat): 3273, 2950, 1716, 1583, 
1539 cm-1. HRMS: exact mass calculated for [M+H]+ (C16H15N2O3S) requires m/z 315.0798, 
found m/z 315.0798. 
6-((6-Methoxy-2-methyl-1H-indol-3-yl)thio)picolinic acid (27). Prepared according to General 
Procedure 3 using ethyl 6-((6-methoxy-2-methyl-1H-indol-3-yl)thio)picolinate (88) (46 mg, 
0.134 mmol, 1 equiv.) and 2 M aq. NaOH (0.5 mL) in THF (0.5 mL, 0.3 M). Purified using 
MDAP to afford the title compound as a brown amorphous solid (36 mg, 86%). 1H NMR (400 
MHz, MeOD): δ 7.75 (dd, J = 7.6, 0.9 Hz, 1H), 7.58-7.51 (m, 1H), 7.21 (d, J = 8.6 Hz, 1H), 6.93 
(d, J = 2.1 Hz, 1H), 6.78 (dd, J = 8.1, 0.9 Hz, 1H), 6.70 (dd, J = 8.6, 2.2 Hz, 1H), 3.80 (s, 3H), 
2.44 (s, 3H). NH and CO2H protons not observed.
 13C NMR (101 MHz, MeOD): δ 165.8, 164.2, 
156.7, 147.1, 140.9, 137.9, 136.9, 123.5, 122.7, 120.1, 118.0, 109.7, 94.8, 94.7, 54.7, 10.4. υmax 
(neat): 3286, 2995, 1724, 1627, 1581, 1500 cm-1. HRMS: exact mass calculated for [M-H]- 
(C16H13N2O3S) requires m/z 315.0798, found m/z 315.0798. 
6-((2-Methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)picolinic acid (28). Prepared 
according General Procedure 4 using ethyl 6-((2-methyl-1H-indol-3-yl)thio)picolinate (36) (198 
mg, 0.635 mmol, 1 equiv.), 4-bromo-1-methyl-1H-pyrazole (198 µL, 1.90 mmol, 3 equiv.), 
K2CO3 (114 mg, 0.826 mmol, 1.3 equiv.), and CuO (102 mg, 1.27 mmol, 2 equiv.) in pyridine (2 
mL, 0.3 M). Purified using reverse-phase HPLC to afford the title compound as a yellow 
amorphous solid (15 mg, 6%). 1H NMR (400 MHz, CO(CD3)2) δ 11.03 (br s, 1H), 8.08 (s, 1H), 
7.81 (d, J = 7.4 Hz, 1H), 7.76 Ð 7.61 (m, J = 7.8 Hz, 2H), 7.48 (d, J = 7.4 Hz, 1H), 7.30 Ð 7.11 
(m, 3H), 6.99 (d, J = 7.9 Hz, 1H), 4.05 (s, 3H), 2.43 (s, 3H). 13C NMR (101 MHz, CO(CD3)2) δ 
165.2, 163.3, 148.1, 145.4, 139.7, 139.4, 137.2, 129.9, 129.1, 123.8, 123.5, 122.2, 120.7, 118.8, 
111.5, 98.0, 55.3, 39.8, 11.6. υmax (neat): 2924, 2852, 1708, 1693, 1573 cm
-1. HRMS: exact mass 
calculated for [M+H]+ (C19H17N4O2S) m/z requires 365.1067, m/z found 365.1070. 
6-((5-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio) picolinic acid (29). 
Prepared according to General Procedure 2 using 1,10-phenanthroline (57 mg, 0.318 mmol, 1 
equiv.), CuI (30 mg, 0.159 mmol, 0.5 equiv.), Cs2CO3 (207 mg, 0.636 mmol, 2 equiv.), 4-iodo-1-
methyl-1H-pyrazole (132 mg, 0.636 mmol, 2 equiv.), and ethyl 6-((5-chloro-2-methyl-1H-indol-
3-yl)thio)picolinate (82) (110 g, 0.318 mmol, 1 equiv.) in DMF (1 mL, 0.3 M). Purified using 
MDAP to afford the title compound as a white amorphous solid (28 mg, 21%). 1H NMR (400 
MHz, CDCl3): δ 7.88 (d, J = 7.5 Hz, 1H), 7.65-7.61 (m, 3H), 7.50 (d, J = 1.7 Hz, 1H), 7.19-7.05 
(m, 3H), 4.05 (s, 3H), 2.38 (s, 3H). CO2H proton not observed.
 13C NMR (101 MHz, CDCl3): δ 
163.6, 161.3, 145.9, 145.6, 138.6, 137.1, 137.0, 130.2, 127.7, 127.5, 124.0, 123.2, 119.4, 118.0, 
111.7, 97.2, 39.9, 11.7. One carbon not observed/coincident. υmax (neat): 3025, 1730, 1577, 
1558, 1531 cm-1. HRMS: exact mass calculated for [M+H]+ (C19H16ClN4O2S) m/z requires 
399.0677, m/z found 399.0680. 
6-((4-Fluoro-2-methyl-1-(1-methyl-1H-pyrazol-3-yl)-1H-indol-3-yl)thio)picolinic acid (30). 
Prepared according to General Procedure 2 using 1,10-phenanthroline (80 mg, 0.442 mmol, 1 
equiv.), CuI (42 mg, 0.221 mmol, 0.5 equiv.), Cs2CO3 (288 mg, 0.884 mmol, 2 equiv.), 4-iodo-1-
methyl-1H-pyrazole (184 mg, 0.884 mmol, 2 equiv.), and ethyl 6-((7-chloro-2-methyl-1H-indol-
3-yl)thio)picolinate (83) (146 mg, 0.442 mmol, 1 equiv.) in DMF (1.5 mL, 0.3 M). Purified using 
MDAP to afford the title compound as a red amorphous solid (6 mg, 3%). 1H NMR (600 MHz, 
CDCl3): δ 7.87 (d, J = 7.3 Hz, 1H), 7.67 (d, J = 7.4 Hz, 1H), 7.63 (s, 1H), 7.61 (s, 1H), 7.22 (s, 
1H), 7.11 (dd, J = 12.8, 8.0 Hz, 1H), 7.00 (d, J = 8.2 Hz, 1H), 6.88-6.75 (m, 1H), 4.05 (s, 3H), 
2.37 (s, 3H). CO2H proton not observed. 
13C NMR (151 MHz, CDCl3): δ 162.1, 155.9 (d, 
1
JC-F = 
249.1 Hz), 144.5, 142.2, 141.3 (d, 3JC-F = 9.4 Hz), 138.5, 137.1, 127.6, 124.2, 123.1 (d, 
3
JC-F = 
7.5 Hz), 119.2, 117.5 (d, 2JC-F = 17.9 Hz), 107.3 (d, 
2
JC-F = 18.8 Hz), 106.8 (d, JC-F = 3.3 Hz), 
95.1, 39.9, 11.4. Two carbons not observed/coincident. 19F NMR (376 MHz, CDCl3): δ -126.82. 
υmax (neat): 2800, 2500, 1735, 1577, 1558 cm
-1. HRMS: exact mass calculated for [M+H]+ 
(C19H16FN4O2S) requires m/z 383.0973, found m/z 383.0975. 
6-((6-Fluoro-2-methyl-1-(1-methyl-1H-pyrazol-3-yl)-1H-indol-3-yl)thio) picolinic acid (31). 
Prepared according to General Procedure 2 using 1,10-phenanthroline (55 mg, 0.304 mmol, 1 
equiv.), CuI (29 mg, 0.152 mmol 0.5 equiv.), Cs2CO3 (198 mg, 0.608 mmol, 2 equiv.), 4-iodo-1-
methyl-1H-pyrazole (126 mg, 0.608 mmol, 2 equiv.), and ethyl 6-((6-fluoro-2-methyl-1H-indol-
3-yl)thio)picolinate (84) (100 mg, 0.304 mmol, 1 equiv.) in DMF (1 mL, 0.3 M). Purified using 
MDAP to afford the title compound as a yellow amorphous solid (25 mg, 22%). 1H NMR (600 
MHz, MeOD): δ 8.01 (s, 1H), 7.73 (s, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.56 (app t, J = 7.8 Hz, 1H), 
7.42 (dd, J = 8.1, 5.2 Hz, 1H), 6.93 (d, J = 9.4 Hz, 1H), 6.90-6.86 (m, 2H), 4.03 (s, 3H), 2.39 (s, 
3H). CO2H proton not observed. 
13C NMR (151 MHz, CDCl3): δ 162.1, 155.9 (d, 
1
JC-F = 249.1 
Hz), 144.5, 142.2, 141.3 (d, 3JC-F = 9.4 Hz), 138.5, 137.1, 127.6, 124.2, 123.1 (d, 
3
JC-F = 7.5 Hz), 
119.2, 117.5 (d, 2JC-F = 17.9 Hz), 107.3 (d, 
2
JC-F = 18.8 Hz), 106.8 (d, JC-F = 3.3 Hz), 95.1, 39.9, 
11.4. Two carbons not observed/coincident. υmax (neat): 2900, 1725, 1618, 1575, 1558 cm
-1. 
HRMS: exact mass calculated for [M+H]+ (C19H16FN4O2S) requires m/z 383.0973, found m/z 
383.0979. 
6-((2,6-Dimethyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)picolinic acid (33). 
Prepared according to General Procedure 2 using 1,10-phenanthroline (49 mg, 0.270 mmol, 1 
equiv.), CuI (26 mg, 0.135 mmol, 0.5 equiv.), Cs2CO3 (176 mg, 0.540 mmol, 2 equiv.), 4-iodo-1-
methyl-1H-pyrazole (112 mg, 0.540 mmol, 2 equiv.), and ethyl 6-((2,6-dimethyl-1H-indol-3-
yl)thio)picolinate (86) (88 mg, 0.270 mmol, 1 equiv.) in DMF (1 mL, 0.3 M). Purified using 
MDAP to afford 6-((2,6-dimethyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)picolinic 
acid (33) as a yellow amorphous solid (28 mg, 27%): 1H NMR (400 MHz, MeOD): δ 7.99 (s, 
1H), 7.72 (d, J = 0.6 Hz, 1H), 7.68 (d, J = 7.4 Hz, 1H), 7.51 (app t, J = 7.8 Hz, 1H), 7.33 (d, J = 
8.0 Hz, 1H), 7.01 (s, 1H), 6.97 (d, J = 8.0 Hz, 1H), 6.72 (d, J = 8.0 Hz, 1H), 4.03 (s, 3H), 2.40 (s, 
3H), 2.38 (s, 3H). CO2H proton not observed.
 13C NMR (125 MHz, DMSO-d6): δ 147.1, 143.1, 
141.2, 140.5, 136.4, 132.6, 130.8, 126.5, 125.0, 124.8, 123.4, 121.6, 113.9, 42.2, 24.2, 14.0. Four 
carbons not observed/coincident. υmax (neat): 2921, 2852, 1680, 1615, 1558, 1573 cm
-1. HRMS: 
exact mass calculated for [M+H]+ (C20H19N4O2S) requires m/z 379.1223, found m/z 379.1220. 
6-((4-Methoxy-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio) picolinic acid 
(34). Prepared according to General Procedure 2 using 1,10-phenanthroline (53 mg, 0.292 mmol, 
1 equiv.), CuI (28 mg, 0.146 mmol, 0.5 equiv.), Cs2CO3 (190 mg, 0.584 mmol, 2 equiv.), 4-iodo-
1-methyl-1H-pyrazole (121 mg, 0.584 mmol, 2 equiv.), and ethyl 6-((4-methoxy-2-methyl-1H-
indol-3-yl)thio)picolinate (89) (100 mg, 0.292 mmol, 1 equiv.) in DMF (2 mL, 0.1 M). Purified 
using MDAP to afford the title compound as an off-white amorphous solid (21 mg, 18%). 1H 
NMR (600 MHz, MeOD): δ 7.96 (s, 1H), 7.68 (s, 1H), 7.60 (d, J = 7.3 Hz, 1H), 7.47 (app t, J = 
7.8 Hz, 1H), 7.07 (app t, J = 8.1 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 6.75 (d, J = 7.8 Hz, 1H), 6.59 
(d, J = 7.8 Hz, 1H), 4.02 (s, 3H), 3.64 (s, 3H), 2.35 (s, 3H). CO2H proton not observed.
 13C NMR 
(151 MHz, MeOD): δ 163.9, 153.8, 142.3, 140.4, 136.6, 136.6, 128.7, 123.0, 120.5, 119.6, 
118.6, 118.2, 110.0, 103.3, 102.0, 97.5, 54.5, 38.2, 9.9. One carbon not observed/coincident. υmax 
(neat): 3150, 2900, 2800, 1602, 1556 cm-1. HRMS: exact mass calculated for [M+H]+ 
(C20H19N4O3S) requires m/z 395.1172, found m/z 395.1174. 
6-((6-Methoxy-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio) picolinic acid 
(35). Prepared according to General Procedure 2 using 1,10-phenanthroline (56 mg, 0.311 mmol, 
1 equiv.), CuI (30 mg, 0.156 mmol, 0.5 equiv.), Cs2CO3 (203 mg, 0.622 mmol, 2 equiv.), 4-iodo-
1-methyl-1H-pyrazole (129 mg, 0.622 mmol, 2 equiv.), and ethyl 6-((6-methoxy-2-methyl-1H-
indol-3-yl)thio)picolinate (88) (106 mg, 0.311 mmol, 1 equiv.) in DMF (1 mL, 0.3 M). Purified 
using MDAP to afford the title compound as a pink amorphous solid (32 mg, 26%). 1H NMR 
(600 MHz, CDCl3): δ 7.85 (d, J = 7.4 Hz, 1H), 7.65 (s, 1H), 7.63-7.58 (m, 2H), 7.38 (d, J = 8.6 
Hz, 1H), 7.09 (d, J = 8.1 Hz, 1H), 6.83 (dd, J = 8.6, 2.1 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 4.05 
(s, 3H), 3.79 (s, 3H), 2.35 (s, 3H). CO2H proton not observed.
 13C NMR (151 MHz, CDCl3): δ 
163.8, 162.1, 157.3, 145.8, 142.8, 139.5, 138.5, 137.1, 127.6, 124.0, 122.9, 119.5, 119.2, 119.1, 
111.0, 97.2, 94.6, 55.8, 39.8, 11.6. υmax (neat): 3300, 1755, 1616, 1583, 1556 cm
-1. HRMS: exact 
mass calculated for [M+H]+ (C20H19N4O3S) requires m/z 395.1172, found m/z 395.1173. 
Ethyl 6-((2-methyl-1H-indol-3-yl)thio)picolinate (36). Prepared according to the General 
Procedure 1 using ethyl 6-((2-oxopropyl)thio)picolinate (13) (1 g, 4.24 mmol, 1 equiv.), and 
phenylhydrazine hydrochloride (615 mg, 4.24 mmol, 1 equiv.) in tBuOH (50 mL, 0.1 M), with 
additional 1 M HCl in Et2O (0.6 mL) and AcOH (0.6 mL). Purified using silica chromatography, 
eluting with 10-80% EtOAc/petroleum ether, to afford the title compound as a brown amorphous 
solid (1.23 g, 93%). 1H NMR (400 MHz, CDCl3): δ 8.59 (br s, 1H), 7.74 (dd, J = 7.6, 0.8 Hz, 
1H), 7.51 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.37 (d, J = 8.7 Hz, 1H), 7.24-7.19 (m, 
1H), 7.13 (td, J = 7.7, 1.0 Hz, 1H), 6.76 (d, J = 8.1 Hz, 1H), 4.47 (q, J = 7.1 Hz, 2H), 2.53 (s, 
3H), 1.43 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 165.1, 164.1, 148.0, 141.6, 137.2, 
135.7, 129.8, 122.5, 122.4, 120.9, 120.5, 118.8, 110.9, 97.8, 61.9, 14.3, 12.2. υmax (neat): 3281, 
1732, 1716, 1573 cm-1. HRMS: exact mass calculated for [M+H]+ (C17H17N2O2S) m/z requires 
313.1005, m/z found 313.1005. 
6-((1,2-Dimethyl-1H-indol-3-yl)thio)picolinic acid (37). Prepared according to General 
Procedure 6 using methyl ethyl 6-((2-methyl-1H-indol-3-yl)thio)picolinate (36) (301 mg, 0.965 
mmol, 1 equiv.), NaH 95% w/w (73 mg, 2.89 mmol, 3 equiv.), and MeI (120 µL, 1.93 mmol, 2 
equiv.) in DMF (3 mL, 0.3 M). The crude material was then used in General Procedure C using 2 
M aq. NaOH (0.25 mL). Purified by reverse-phase HPLC to afford the title compound as a dark 
red amorphous solid (35 mg, 12% over 2 steps). 1H NMR (500 MHz, CDCl3): δ 7.83 (d, J = 7.5 
Hz, 1H), 7.57 (dd, J = 9.7, 5.9 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.29 
(d, J = 7.3 Hz, 1H), 7.17 (app t, J = 7.4 Hz, 1H), 6.98 (d, J = 8.1 Hz, 1H), 3.81 (s, 3H), 2.53 (s, 
3H). CO2H proton not observed. 
13C NMR (101 MHz, CDCl3): δ 145.2, 138.0, 137.9, 123.5, 
123.4, 122.2, 121.8, 120.7, 120.5, 118.6, 118.5, 118.0, 110.5, 108.9, 29.2, 10.4. υmax (neat): 
2992, 2852, 1693, 1571, 1550 cm-1. HRMS: exact mass calculated for [M+H]+ (C16H15N2O2S) 
requires m/z 299.0854, found m/z 299.0853 
6-((1-Cyclopentyl-2-methyl-1H-indol-3-yl)thio)picolinic acid (38). Prepared according to 
General Procedure 6 using ethyl 6-((2-methyl-1H-indol-3-yl)thio)picolinate (36) (300 mg, 0.962 
mmol, 1 equiv.), NaH 60% w/w (116 mg, 2.89 mmol, 3 equiv.), and bromocyclopentane (309 
µL, 2.89 mmol, 3 equiv.) in DMF (3 mL, 0.3 M). Purified by reverse-phase HPLC to afford the 
title compound as a yellow amorphous solid (36 mg, 11%). 1H NMR (400 MHz, CDCl3): δ 9.10 
(s, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.41-7.37 (m, 2H), 7.24-7.19 (m, 1H), 
7.16-7.11 (m, 1H), 6.79 (d, J = 8.7 Hz, 1H), 5.49-5.44 (m, 1H), 2.53 (s, 3H), 2.07-1.96 (m, 2H), 
1.93-1.75 (m, 4H), 1.67-1.62 (m, 2H). 13C NMR (101 MHz, CDCl3): δ 164.3, 163.7, 147.7, 
141.4, 136.7, 135.3, 129.3, 121.9, 121.8, 120.3, 119.9, 118.1, 110.6, 96.9, 78.3, 32.2, 23.3, 11.7. 
υmax (neat): 3275, 2918, 1714, 1570 cm
-1. HRMS: exact mass calculated for [M-H]- 
(C20H19N2O2S) requires m/z 351.1173, found m/z 351.1170. 
6-((2-Methyl-1-phenyl-1H-indol-3-yl)thio)picolinic acid (39). Prepared according to General 
Procedure 4 using ethyl 6-((2-methyl-1H-indol-3-yl)thio)picolinate (36) (200 mg, 0.641 mmol, 1 
equiv.), bromobenzene (204 µL, 1.92 mmol, 3 equiv.), CuO (102 mg, 1.28 mmol, 2 equiv.), and 
K2CO3 (115 mg, 0.833 mmol, 1.3 equiv.) in pyridine (2 mL, 0.3 M). Purified by reverse-phase 
HPLC to afford the title compound as a brown amorphous solid (12 mg, 5%). 1H NMR (400 
MHz, CDCl3): δ 7.87 (d, J = 7.4 Hz, 1H), 7.67-7.49 (m, 5H), 7.41-7.39 (m, 2H), 7.23-7.14 (m, 
3H), 7.12 (d, J = 8.0 Hz, 1H), 2.39 (s, 3H). CO2H proton not observed.
 13C NMR (101 MHz, 
CDCl3): δ 163.2, 161.6, 145.3, 142.9, 138.0, 137.7, 136.7, 129.3, 128.2, 127.4, 123.6, 122.3, 
121.1, 118.7, 118.0, 110.3, 96.9, 11.2. υmax (neat): 2920, 2850, 1693, 1573, 1550 cm
-1. HRMS: 
exact mass calculated for [M+H]+ (C21H17N2O2S) requires m/z 361.1010, found m/z 361.1010. 
6-((6-Chloro-1,2-dimethyl-1H-indol-3-yl)thio)picolinic acid (40). Prepared according to 
General Procedure 6 using ethyl 6-((6-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (16) (138 
mg, 0.399 mmol, 1 equiv.), NaH 60% w/w (64 mg, 1.60 mmol, 4 equiv.), and MeI (74 µL, 1.19 
mmol, 3 equiv.) in DMF (2 mL, 0.2 M). Purified using reverse-phase HPLC to afford the title 
compound as a yellow amorphous solid (28 mg, 21%). 1H NMR (400 MHz, CDCl3): δ 7.84 (d, J 
= 7.3 Hz, 1H), 7.58 (app t, J = 7.8 Hz, 1H), 7.43-7.36 (m, 2H), 7.12 (d, J = 8.3 Hz, 1H), 6.94 (d, 
J = 7.9 Hz, 1H), 3.76 (s, 3H), 2.51 (s, 3H). CO2H proton not observed.
 13C NMR (101 MHz, 
CDCl3): δ 161.6, 143.5, 138.0, 137.2, 127.8, 127.7, 127.1, 123.3, 121.1, 118.9, 118.8, 109.2, 
95.4, 30.2, 29.2, 10.6. υmax (neat): 2916, 2848, 1703, 1573, 1556 cm
-1. HRMS: exact mass 
calculated for [M+H]+ (C16H14ClN2O2S) requires m/z 333.0462, found m/z 333.0463. 
6-((6-Chloro-1-cyclopentyl-2-methyl-1H-indol-3-yl)thio)picolinic acid (41). Prepared 
according to General Procedure 6 using ethyl 6-((6-chloro-2-methyl-1H-indol-3-
yl)thio)picolinate (16) (193 mg, 0.558 mmol, 1 equiv.), NaH 60% w/w (178 mg 4.46 mmol, 8 
equiv.), and bromocyclopentane (359 µL, 3.35 mmol, 6 equiv.) in DMF (3 mL, 0.2 M). Purified 
by reverse-phase HPLC to afford the title compound as an off white solid (19 mg, 10%). 1H 
NMR (400 MHz, CDCl3): δ 7.85 (dd, J = 7.5, 0.8 Hz, 1H), 7.65-7.57 (m, 1H), 7.48-7.43 (m, 2H), 
7.42 (s, 1H), 7.11 (dd, J = 8.4, 1.7 Hz, 1H), 6.96 (dd, J = 8.1, 0.8 Hz, 1H), 4.85 (m, 1H), 2.54 (s, 
3H), 2.33-2.20 (m, 2H), 2.20-2.04 (m, 4H), 1.90-1.77 (m, 2H). 13C NMR (126 MHz, CDCl3): δ 
163.6, 162.1, 145.7, 144.1, 138.5, 135.2, 128.6, 127.7, 123.9, 121.3, 119.7, 119.2, 111.6, 96.1, 
57.5, 30.2, 25.2, 11.9. υmax (neat): 2958, 2872, 1699, 1570 cm
-1. HRMS: exact mass calculated 
for [M-H]- (C20H18ClN2O2S) requires m/z 385.0783, found m/z 385.0778. 
6-((6-Chloro-2-methyl-1-phenyl-1H-indol-3-yl)thio)picolinic acid (42). Prepared according to 
General Procedure 2 using 1,10-phenanthroline (104 mg, 0.578 mmol, 1 equiv.), CuI (55 mg, 
0.289 mmol, 0.5 equiv.), Cs2CO3 (377 mg, 1.15 mmol, 2 equiv.), iodobenzene (147 µL, 1.15 
mmol, 2 equiv.), and ethyl 6-((6-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (16) (200 mg, 
0.578 mmol, 1 equiv.) in DMF (2 mL, 0.1 M). Purified using MDAP to afford the title 
compound as a white amorphous solid (9 mg, 4%). 1H NMR (500 MHz, MeOD): δ 7.88 (d, J = 
7.3 Hz, 1H), 7.66 (app t, J = 7.8 Hz, 1H), 7.61 (app t, J = 7.4 Hz, 2H), 7.55 (app t, J = 7.4, 1H), 
7.47 (d, J = 8.4 Hz, 1H), 7.40-7.36 (m, 2H), 7.19-7.13 (m, 2H), 7.11 (d, J = 8.1 Hz, 1H), 2.37 (s, 
3H). CO2H proton not observed.
 13C NMR (151 MHz, MeOD): δ 162.6, 144.6, 138.6, 137.8, 
136.8, 129.8, 128.8, 128.3, 127.8, 127.7, 122.1, 121.5, 120.2, 119.1, 110.1, 110.0, 98.3, 10.3. 
One carbon not observed/coincident. υmax (neat): 3051, 1771, 1598, 1559, 1501 cm
-1. HRMS: 
exact mass calculated for [M+H]+ (C21H16ClN2O2S) requires m/z 395.0616, found m/z 395.0617. 
1-((3-Bromophenyl)thio)propan-2-one (44). A flask containing 3-bromothiophenol (43) (273 
µL, 2.65 mmol, 1 equiv.) in THF (15 mL, 0.2 M) was cooled to 0 ¡C. DIPEA (2.3 mL, 13.2 
mmol, 5 equiv.) was added portion wise and allowed to stir for 30 min before the addition of 
chloroacetone (2.3 mL, 29.0 mmol, 11 equiv.). The reaction mixture was then allowed to warm 
to room temperature and stirred for 16 h. The reaction mixture was concentrated under vacuum, 
diluted with EtOAc (30 mL) and washed with H2O (30 mL). The organic layer was collected, 
dried (hydrophobic frit), and concentrated under vacuum. Purified using silica chromatography, 
eluting with 0-40% EtOAc/petroleum ether, to afford the title compound as a colourless oil (540 
mg, 83%). 1H NMR (400 MHz, CDCl3): δ 7.45 (app t, J = 1.8 Hz, 1H), 7.33-7.29 (m, 1H), 7.24-
7.20 (m, 1H), 7.13 (t, J = 7.9 Hz, 1H), 3.68 (s, 2H), 2.26 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 
202.8, 137.2, 131.6, 130.4, 129.8, 127.6, 122.9, 44.3, 28.1. υmax (neat): 3050, 1571, 1559 cm
-1. 
HRMS: exact mass calculated for [M+H]+ (C9H10BrOS) requires m/z 246.9609, found m/z 
246.9601.  
3-((3-Bromophenyl)thio)-6-chloro-2-methyl-1H-indole (45). Prepared according to General 
Procedure 5 using (3-chlorophenyl)hydrazine hydrochloride (1.5 g, 8.18 mmol, 1 equiv.) and 1-
((3-bromophenyl)thio)propan-2-one (44) (2 g, 8.18 mmol, 1 equiv.) in EtOH (40 mL, 0.2 M). 
Purified by silica chromatography, eluting with 0-10% EtOAc/petroleum ether, to afford the title 
compound as a cream amorphous solid (639 mg, 22%). 1H NMR (400 MHz, CO(CD3)2) δ: 10.97 
(br s, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.26-7.23 (m, 1H), 7.15 (app t, J = 
7.9 Hz, 1H), 7.11 (app t, J = 1.8 Hz, 1H), 7.08 (dd, J = 8.4 Hz, 1H), 7.03-7.01 (m, 1H), 2.52 (s, 
3H). 13C NMR (101 MHz, CDCl3): δ 143.0, 142.8, 136.3, 132.2, 129.5, 127.3, 127.0, 125.4, 
123.4, 122.4, 122.2, 121.8, 109.1, 97.8, 11.7. υmax (neat): 3409, 1573, 1557, 1536 cm
-1. HRMS: 
exact mass calculated for [M+H]+ (C15H12BrClNS) m/z requires 353.9534, m/z found 353.9529. 
 
Methyl 3-((6-chloro-2-methyl-1H-indol-3-yl)thio)benzoate (46). Prepared according to 
General Procedure 7 using trans-bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) 
(90 mg, 0.0959 mmol, 5 mol%), 3-((3-bromophenyl)thio)-6-chloro-2-methyl-1H-indole (45) 
(639 mg, 1.81 mmol, 1 equiv.), Mo(CO)6 (478 mg, 1.81 mmol, 1 equiv.), [tBu3PH]BF4 (112 mg, 
0.386 mmol, 20 mol%), and DBU (433 µL, 2.90 mmol, 1.6 equiv.) in MeCN/MeOH (20 mL, 
1:4, 0.3 M). Purified by column chromatography, eluting with 0-20% EtOAc/petroleum ether, to 
afford the title compound as a cream amorphous solid (463 mg, 77%). 1H NMR (400 MHz, 
CO(CD3)2) δ: 10.92 (br s, 1H), 7.73-7.66 (m, 2H), 7.47 (d, J = 1.8 Hz, 1H), 7.38 (d, J = 8.4 Hz, 
1H), 7.34-7.30 (m, 1H), 7.25-7.18 (m, 1H), 7.07 (dd, J = 8.4, 1.9 Hz, 1H), 3.81 (s, 3H), 2.53 (s, 
3H). 13C NMR (101 MHz, CO(CD3)2) δ: 166.8, 144.4, 141.2, 137.4, 131.9, 130.6, 130.0, 129.7, 
128.1, 126.9, 126.6, 121.6, 120.0, 112.1, 98.4, 52.4, 12.0. υmax (neat): 3405, 3321, 2950, 1699, 
1621, 1591, 1575, 1539 cm-1. HRMS: exact mass calculated for [M+H]+ (C17H15ClNO2S) m/z 
requires 334.0476, m/z found 334.0474.  
3-((6-Chloro-1,2-dimethyl-1H-indol-3-yl)thio)benzoic acid (47). Prepared according to 
General Procedure 6 using methyl 3-((6-chloro-2-methyl-1H-indol-3-yl)thio)benzoate (46) (200 
mg, 0.604 mmol, 1 equiv.), NaH 60% w/w (193 mg, 4.82 mmol, 8 equiv.) and MeI (150 µL, 2.41 
mmol, 4 equiv.) in DMF (3 mL, 0.2 M). Following aqueous work-up, the reaction mixture was 
then used in the next step without further purification. The crude material was used according to 
General Procedure 3 using 4 M aq. NaOH (5 mL) in THF (3 mL, 0.2 M). Purified by reverse-
phase HPLC to afford the title compound as a cream amorphous solid (2 mg, 1% over 2 steps). 
1H NMR (400 MHz, CDCl3) δ: 7.82-7.73 (m, 2H), 7.43 (d, J = 8.4 Hz, 1H), 7.35 (d, J = 1.7 Hz, 
1H), 7.23 (app t, J = 7.7 Hz, 1H), 7.19-7.13 (m, 1H), 7.09 (dd, J = 8.4, 1.8 Hz, 1H), 3.75 (s, 3H), 
2.51 (s, 3H). CO2H proton not observed. 
13C NMR (151 MHz, CDCl3) δ: 170.1, 144.0, 140.6, 
137.7, 130.6, 129.8, 129.0, 128.2, 128.1, 127.2, 126.6, 121.4, 119.8, 109.5, 98.0, 30.7, 11.1. υmax 
(neat): 3436, 2900, 2651, 2543, 1679, 1574 cm-1. HRMS: exact mass calculated for [M-H]- 
(C17H13ClNO2S) m/z requires 332.0330, m/z found 332.0324.  
3-((4-Chloro-2-methyl-1H-indol-3-yl)thio)benzoic acid (48) and 3-((6-chloro-2-methyl-1H-
indol-3-yl)thio)benzoic acid (49). Prepared according to General Procedure 5 using (3-
chlorophenyl)hydrazine hydrochloride (3.3 g, 18.6 mmol, 1 equiv.) and 1-((3-
bromophenyl)thio)propan-2-one (44) (4.6 g, 18.6 mmol, 1 equiv.) in EtOH (90 mL, 0.2 M). 
Following aqueous work-up, the reaction mixture was then used in the next step without further 
purification. The crude material was used according to General Procedure 7 using trans-
bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (200 mg, 0.213 mmol, 1 mol%), 
Mo(CO)6 (4.9 g, 18.6 mmol, 1 equiv.), [tBu3PH]BF4 (1.08 g, 3.72 mmol, 20 mol%), and DBU 
(4.2 mL, 27.9 mmol, 1.5 equiv.) in MeCN/4 M aq. NaOH (60 mL, 1:4, 0.3 M). 1 g of crude 
material was purified by MDAP to afford 3-((4-chloro-2-methyl-1H-indol-3-yl)thio)benzoic acid 
(48) as a cream amorphous solid (100 mg, 2% over 2 steps) and 3-((6-chloro-2-methyl-1H-indol-
3-yl)thio)benzoic acid (49) as a cream amorphous solid (70 mg, 1% over 2 steps). 3-((4-Chloro-
2-methyl-1H-indol-3-yl)thio)benzoic acid (48): 1H NMR (400 MHz, CO(CD3)2) δ: 11.04 (br s, 
1H), 7.80-7.69 (m, 2H), 7.40 (dd, J = 7.8, 1.0 Hz, 1H), 7.35-7.27 (m, 1H), 7.23 (d, J = 8.2 Hz, 
1H), 7.13-6.98 (m, 2H), 2.53 (s, 3H). CO2H proton not observed. 
13C NMR (101 MHz, 
CO(CD3)2) δ: 167.9, 145.3, 143.0, 138.5, 132.3, 130.2, 129.6, 126.9, 126.7, 126.5, 125.8, 123.1, 
122.3, 111.2, 97.7, 12.0. υmax (neat): 3410, 2869, 2658, 2543, 1681, 1569, 1537 cm
-1. HRMS: 
exact mass calculated for [M+H]+ (C16H13ClNO2S) m/z requires 318.0174, m/z found 318.0167. 
3-((6-Chloro-2-methyl-1H-indol-3-yl)thio)benzoic acid (49): 1H NMR (400 MHz, CO(CD3)2) δ: 
10.84 (br s, 1H), 7.76-7.72 (m, 2H), 7.47 (d, J = 1.8 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.32 (app 
t, J = 7.5 Hz, 1H), 7.26-7.23 (m, 1H), 7.07 (dd, J = 8.4, 1.9 Hz, 1H), 2.53 (s, 3H). CO2H proton 
not observed. 13C NMR (101 MHz, CO(CD3)2) δ: 167.3, 144.3, 141.0, 137.4, 132.1, 130.5, 
129.8, 129.7, 128.0, 127.2, 126.9, 121.5, 120.0, 112.1, 98.5, 12.0. υmax (neat): 3385, 2850, 2665, 
2549, 1667, 1591, 1570, 1539 cm-1. HRMS: exact mass calculated for [M+H]+ (C16H13ClNO2S) 
m/z requires 318.0174, m/z found 318.0163.  
3-((6-Chloro-1-cyclopentyl-2-methyl-1H-indol-3-yl)thio)benzoic acid (50). Prepared 
according to General Procedure 6 using methyl 3-((6-chloro-2-methyl-1H-indol-3-
yl)thio)benzoate (46) (25 mg, 0.0755 mmol, 1 equiv.), NaH 60% w/w (24 mg, 0.602 mmol, 8 
equiv.) and bromocyclopentane (32 µL, 0.301 mmol, 4 equiv.) in DMF (1 mL, 0.1 M). 
Following aqueous work-up, the reaction mixture was then used in the next step without further 
purification. The crude material was used according to General Procedure 3 using 4 M aq. NaOH 
(1 mL) in THF (1 mL, 0.1 M). Purified using silica chromatography, eluting with 0-20% 
EtOAc/petroleum ether, to afford the title compound as a pale yellow gum (2 mg, 7% over 2 
steps). 1H NMR (400 MHz, CO(CD3)2) δ: 7.78-7.69 (m, 2H), 7.59 (d, J = 1.7 Hz, 1H), 7.46 (d, J 
= 8.4 Hz, 1H), 7.32 (app t, J = 7.8 Hz, 1H), 7.21-7.18 (m, 1H), 7.09 (dd, J = 8.4, 1.8 Hz, 1H), 
5.20-5.04 (m, 1H), 2.62 (s, 3H), 2.28-2.19 (m, 4H), 2.16-2.06 (m, 2H), 1.91-1.78 (m, 2H). CO2H 
proton not observed. 13C NMR (151 MHz, CO(CD3)2) δ: 145.9, 141.1, 136.4, 130.6, 130.2, 
130.0, 127.9, 127.4, 127.1, 121.6, 120.7, 112.4, 98.8, 58.4, 30.8, 25.8, 12.1. Two carbons not 
observed/coincident. υmax (neat): 3406, 2924, 2872, 1716, 1608, 1593, 1577, 1534 cm
-1. HRMS: 
exact mass calculated for [M+H]+ (C21H21ClNO2S) m/z requires 388.0945, m/z found 388.0948. 
3-((6-Chloro-2-methyl-1-phenyl-1H-indol-3-yl)thio)benzoic acid (51). Prepared according to 
General Procedure 2 using 3-((6-chloro-2-methyl-1H-indol-3-yl)thio)benzoic acid (49) (65 mg, 
0.205 mmol, 1 equiv.), iodobenzene (46 µL, 0.409 mmol, 2 equiv.), CuI (19 mg, 0.102 mmol, 
0.5 equiv.), Cs2CO3 (133 mg, 0.409 mmol, 2 equiv.), and 1,10-phenanthroline (37 mg, 0.205 
mmol, 1 equiv.) in DMF (1 mL, 0.2 M). Purified by reverse-phase HPLC to afford the title 
compound as a white amorphous solid (11 mg, 14%). 1H NMR (400 MHz, CO(CD3)2) δ: 7.81 
(dd, J = 2.4, 1.1 Hz, 1H), 7.77 (dt, J = 7.3, 1.5 Hz, 1H), 7.73-7.66 (m, 2H), 7.66-7.59 (m, 1H), 
7.59-7.54 (m, 2H), 7.51(d, J = 8.4 Hz, 1H), 7.40-7.27 (m, 2H), 7.16 (dd, J = 8.4, 1.8 Hz, 1H), 
7.13-7.08 (m, 1H), 2.41 (s, 3H). CO2H proton not observed. 
13C NMR (101 MHz, CO(CD3)2) δ: 
165.7, 144.1, 139.0, 138.0, 136.3, 130.9, 129.5, 129.3, 128.6, 128.5, 127.4, 126.0, 125.7, 121.0, 
119.0, 109.8, 99.0, 10.4. Two carbons not observed/coincident. υmax (neat): 3058, 2978, 2924, 
2658, 1690, 1593, 1577, 1536, 1502 cm-1. HRMS: exact mass calculated for [M-H]- 
(C22H15ClNO2S) m/z requires 394.0487, m/z found 394.0480. 
 
3-((6-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)benzoic acid (52). 
Prepared according to General Procedure 3 using methyl 3-((6-chloro-2-methyl-1-(1-methyl-1H-
pyrazol-4-yl)-1H-indol-3-yl)thio)benzoate (90) (68 mg, 0.165 mmol, 1 equiv.) and 4 M aq. 
NaOH (1 mL) in THF (1 mL, 0.2 M). Purified using silica chromatography, eluting with 10% 
MeOH/DCM, to afford the title compound as a cream amorphous solid (16 mg, 24%). 1H NMR 
(500 MHz, CO(CD3)2): δ 11.29 (br s, 1H), 8.09 (s, 1H), 7.80 (s, 1H), 7.76 (d, J = 7.6 Hz, 1H), 
7.72 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.35 (app t, J = 7.7 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 7.22 
(s, 1H), 7.14 (dd, J = 8.4, 1.7 Hz, 1H), 4.04 (s, 3H), 2.42 (s, 3H). 13C NMR (126 MHz, 
CO(CD3)2): δ 146.4, 140.4, 140.0, 137.2, 132.3, 130.8, 130.0, 129.2, 129.0, 128.8, 127.5, 127.2, 
122.4, 120.3, 119.3, 111.4, 100.0, 39.9, 11.7. One carbon not observed/coincident. υmax (neat): 
2920, 2848, 1718, 1571, 1537 cm-1. HRMS: exact mass calculated for [M-H]- (C20H15ClN3O2S) 
m/z requires 398.0548, m/z found 398.0539. 
3-((2-Methyl-1H-indol-3-yl)thio)benzoic acid (53). Prepared according to General Procedure 3 
using methyl 3-((2-methyl-1H-indol-3-yl)thio)benzoate (92) (100 mg, 0.337 mmol, 1 equiv.) and 
2 M aq. NaOH (1 mL) in THF (1 mL, 0.3 M). Purified by reverse-phase HPLC to afford the title 
compound as a cream amorphous solid (71 mg, 74%). 1H NMR (400 MHz, CO(CD3)2): δ 10.71 
(br s, 1H), 7.76 (app t, J = 1.5 Hz, 1H), 7.74-7.72 (m, 1H), 7.48-7.39 (m, 2H), 7.30 (app t, J = 7.7 
Hz, 1H), 7.25-7.22 (m, 1H), 7.15-7.11 (m, 1H), 7.07-7.04 (m, 1H), 2.53 (s, 3H). One 
exchangeable proton not observed. 13C NMR (101 MHz, CO(CD3)2): δ 167.4, 143.1, 141.6, 
137.0, 132.1, 131.0, 130.4, 129.7, 127.1, 126.7, 122.7, 121.1, 118.8, 112.1, 97.9, 12.0. υmax 
(neat): 3390, 3057, 2885, 2654, 2546, 1686, 1570, 1543 cm-1. HRMS: exact mass calculated for 
[M+H]+ (C16H14NO2S) m/z requires 284.0740, m/z found 284.0740. 
3-((1,2-Dimethyl-1H-indol-3-yl)thio)benzoic acid (54). Prepared according to General 
Procedure 3 using methyl 3-((1,2-dimethyl-1H-indol-3-yl)thio)benzoate (93) (54 mg, 0.174 
mmol, 1 equiv.) and 2 M aq. NaOH (1 mL ) in THF (1 mL, 0.2 M). Purified by reverse-phase 
HPLC to afford the title compound as a cream amorphous solid (31 mg, 60%). 1H NMR (400 
MHz, CDCl3): δ 7.84 (app t, J = 1.5Hz, 1H), 7.76-7.74 (m, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.36 
(d, J = 8.2 Hz, 1H), 7.25-7.11 (m, 4H), 3.79 (s, 3H), 2.53 (s, 3H). CO2H proton not observed. 
13C 
NMR (101 MHz, CDCl3): δ 171.1, 143.2, 141.1, 137.3, 130.7, 129.8, 129.7, 128.9, 127.2, 126.4, 
122.1, 120.8, 118.9, 109.3, 97.4, 30.6, 11.0. υmax (neat): 2922, 2546, 1680, 1572, 1521 cm
-1. 
HRMS: exact mass calculated for [M+H]+ (C17H16NO2S) m/z requires 298.0896, m/z found 
298.0893. 
3-((1-Cyclopentyl-2-methyl-1H-indol-3-yl)thio)benzoic acid (55). Prepared according to 
General Procedure 6 using methyl 3-((2-methyl-1H-indol-3-yl)thio)benzoate (92) (200 mg, 0.673 
mmol, 1 equiv.), NaH 60% w/w (216 mg, 5.39 mmol, 8 equiv.), and bromocyclopentane (288 
µL, 2.69 mmol, 4 equiv.) in DMF (3 mL, 0.2 M). Following aqueous work-up, the reaction 
mixture was then used in the next step without further purification. The crude material was used 
according to General Procedure 3 using 4 M aq. NaOH (5 mL) in THF (3 mL, 0.2 M). Purified 
by reverse-phase HPLC to afford the title compound as a white amorphous solid (15 mg, 6% 
over 2 steps). 1H NMR (400 MHz, CO(CD3)2): δ 7.78-7.70 (m, 2H), 7.57 (d, J = 8.3 Hz, 1H), 
7.49 (d, J = 7.5 Hz, 1H), 7.30 (app t, J = 7.7 Hz, 1H), 7.22-7.17 (m, 1H), 7.17-7.12 (m, 1H), 
7.09-7.07 (m, 1H), 5.14-5.05 (m, 1H), 2.61 (s, 3H), 2.37-2.23 (m, 2H), 2.23-2.07 (m, 4H), 1.92-
1.73 (m, 2H). CO2H proton not observed.
 13C NMR (101 MHz, CO(CD3)2): δ 167.2, 144.5, 
141.6, 135.9, 132.1, 131.4, 130.4, 129.8, 127.2, 126.8, 122.3, 121.0, 119.5, 112.5, 97.9, 58.2, 
30.6, 25.8, 11.7. υmax (neat): 3388, 2976, 2954, 2870, 2660, 2539, 1668, 1591, 1571, 1530 cm
-1. 
HRMS: exact mass calculated for [M-H]- (C21H20NO2S) m/z requires 350.1220, m/z found 
350.1216. 
3-((2-Methyl-1-phenyl-1H-indol-3-yl)thio)benzoic acid (56). Prepared according to General 
Procedure 2 using methyl 3-((2-methyl-1H-indol-3-yl)thio)benzoate (92) (127 mg, 0.428 mmol, 
1 equiv.), iodobenzene (95 µL, 0.856 mmol, 2 equiv.), CuI (41 mg, 0.214 mmol, 0.5 equiv.), 
Cs2CO3 (279 mg, 0.856 mmol, 2 equiv.), and 1,10-phenanthroline (77 mg, 0.428 mmol, 1 equiv.) 
in DMF (1 mL, 0.4 M). Following aqueous work-up, the reaction mixture was then used in the 
next step without further purification. The crude material was used according to General 
Procedure 3 using 4 M aq. NaOH (1 mL) in THF (2 mL, 0.2 M). Purified by reverse-phase 
HPLC to afford the title compound as a cream amorphous solid (14 mg, 9% over 2 steps). 1H 
NMR (400 MHz, CDCl3): δ 7.95-7.89 (m, 1H), 7.82-7.76 (m, 1H), 7.63-7.55 (m, 3H), 7.54-7.48 
(m, 1H), 7.41 (dd, J = 8.3, 1.3 Hz, 2H), 7.29-7.26 (m, 2H), 7.20-7.12 (m, 3H), 2.40 (s, 3H). 
CO2H proton not observed.
 13C NMR (101 MHz, CDCl3): δ 143.4, 140.6, 138.2, 137.6, 130.8, 
129.8, 129.6, 129.0, 128.6, 128.1, 127.4, 126.6, 122.6, 121.4, 118.8, 110.6, 99.5, 11.9. Two 
carbons not observed/coincident. υmax (neat): 2917, 2852, 2651, 2536, 1679, 1597, 1571, 1530, 
1501 cm-1. HRMS: exact mass calculated for [M-H]- (C22H16NO2S) m/z requires 358.0907, m/z 
found 358.0900. 
3-((2-Methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)benzoic acid (57). Prepared 
according to General Procedure 4 using methyl 3-((2-methyl-1H-indol-3-yl)thio)benzoate (92) 
(202 mg, 0.680 mmol, 1 equiv.), 4-bromo-1-methyl-1H-pyrazole (209 µL, 2.02 mmol, 3 equiv.), 
CuO (108 mg, 1.35 mmol, 2 equiv.), and K2CO3 (122 mg, 0.884 mmol, 1.3 equiv.) in pyridine (2 
mL, 0.3 M). Purified using reverse-phase HPLC to afford the title compound as a dark red 
amorphous solid (22 mg, 9%). 1H NMR (400 MHz, CDCl3): δ 8.33 (s, 1H), 7.81 (app t, J = 1.7 
Hz, 1H), 7.72-7.69 (m, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.33 (dd, J = 4.8, 3.9 Hz, 1H), 7.21-7.19 
(m, 2H), 7.16-7.12 (m, 2H), 3.86 (s, 3H), 2.51 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 166.9, 
141.3, 140.3, 135.5, 130.6, 130.1, 129.8, 128.7, 126.6, 125.8, 122.3, 120.8, 118.8, 110.8, 98.7, 
52.2, 12.1. Three carbons not observed/coincident. υmax (neat): 3381, 3375, 1695, 1572, 1539 
cm-1. HRMS: exact mass calculated for [M-H]- (C20H16N3O2S) m/z requires 362.0969, m/z found 
362.0967. 
Ethyl 3-(2-oxopropoxy)benzoate (59). Chloroacetone (2.4 mL, 30.1 mmol, 1 equiv.) was added 
to a stirred suspension of ethyl 3-hydroxybenzoate (58) (5 g, 30.1 mmol, 1 equiv.) and K2CO3 
(8.3 g, 60.2 mmol, 2 equiv.) in acetone (150 mL, 0.2 M). The reaction mixture was heated to 60 
¡C for 16 h then allowed to return to room temperature and concentrated under vacuum. The 
residue was then dissolved in EtOAc (100 mL) and washed with water (100 mL), followed by 4 
M aq. NaOH (100 mL). The organic layer was collected, dried (hydrophobic frit), and 
concentrated under vacuum. Purified using silica chromatography, eluting with 10% 
EtOAc/petroleum ether, to afford the title compound as a yellow liquid (3.7 g, 55%). 1H NMR 
(500 MHz, CDCl3): δ 7.70-7.68 (m, 1H), 7.53 (dd, J = 2.6, 1.4 Hz, 1H), 7.37 (app t, J = 8.0 Hz, 
1H), 7.10 (dd, J = 8.2, 2.7, 1H), 4.60 (s, 2H), 4.37 (q, J = 7.1 Hz, 2H), 2.29 (s, 3H), 1.39 (t, J = 
7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 205.0, 166.3, 157.8, 132.3, 129.8, 123.1, 119.8, 
115.0, 73.2, 61.3, 26.8, 14.4. υmax (neat): 2980, 2906, 1714, 1585 cm
-1. HRMS: exact mass 
calculated for [M+H]+ (C12H15O4) m/z requires 223.0965, m/z found 223.0966. 
Ethyl 3-((2-methyl-1H-indol-3-yl)oxy)benzoate (60). Prepared according to General Procedure 
1 using phenylhydrazine hydrochloride (653 mg, 4.50 mmol, 1 equiv.) and ethyl 3-(2-
oxopropoxy)benzoate (59) (1 g, 4.50 mmo, 1 equiv.) in tBuOH (45 mL, 0.1 M) with additional 1 
M HCl in Et2O (14 mL) and AcOH (14 mL). Purified by reverse-phase HPLC to afford the title 
compound as a pale brown amorphous solid (167 mg, 12%). 1H NMR (500 MHz, CDCl3): δ 7.91 
(s, 1H), 7.79-7.71 (m, 2H), 7.34 (app t, J = 8.2 Hz, 1H), 7.28 (app t, J = 7.6 Hz, 2H), 7.20-7.12 
(m, 2H), 7.06 (app t, J = 7.5 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 2.29 (s, 3H), 1.40 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, CDCl3): δ 166.6, 159.4, 133.2, 132.0, 130.0, 129.5, 124.4, 122.9, 
121.7, 121.5, 119.8, 119.7, 117.1, 116.6, 111.0, 61.2, 14.4, 10.1. υmax (neat): 3370, 2980, 1715, 
1697, 1620, 1584 cm-1. HRMS: exact mass calculated for [M+H]+ (C18H18NO3) m/z requires 
296.1281, m/z found 296.1284. 
3-((2-Methyl-1H-indol-3-yl)oxy)benzoic acid (61). Prepared according to General Procedure 3 
using ethyl 3-((2-methyl-1H-indol-3-yl)oxy)benzoate (60) (50 mg, 0.169 mmol, 1 equiv.) and 1 
M aq. NaOH (1 mL) in THF (2 mL, 0.1 M). Purified by reverse-phase HPLC to afford the title 
compound as a brown oil (8 mg, 18%). 1H NMR (400 MHz, CDCl3): δ 7.74-7.71 (m, 1H), 7.70-
7.64 (m, 2H), 7.35 (app t, J = 7.9 Hz, 1H), 7.32-7.28 (m, 1H), 7.24-7.18 (m, 1H), 7.16-7.12 (m, 
1H), 7.07-6.99 (m, 1H), 2.34 (s, 3H). NH and CO2H protons not observed.
 13C NMR (101 MHz, 
CDCl3): δ 170.9, 159.5, 133.3, 130.7, 130.1, 129.7, 124.3, 123.6, 122.0, 121.5, 120.9, 119.9, 
117.2, 116.9, 111.0, 10.4. υmax (neat): 3404, 2920, 2558, 1690, 1584, 1572 cm
-1. HRMS: exact 
mass calculated for [M+H]+ (C16H14NO3) m/z requires 268.0968, m/z found 268.0971. 
3-((2-Methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)oxy)benzoic acid (62). Prepared 
according to General Procedure 4 using ethyl 3-((2-methyl-1H-indol-3-yl)oxy)benzoate (60) (94 
mg, 0.319 mmol, 1 equiv.), 4-bromo-1-methyl-1H-pyrazole (99 µL, 0.956 mmol, 3 equiv.), CuO 
(51 mg, 0.638 mmol, 2 equiv.), and K2CO3 (57 mg, 0.415 mmol, 1.3 equiv.) in pyridine (1 mL, 
0.3 M). Following aqueous work-up, the reaction mixture was then used in the next step without 
further purification. The crude material was used according to General Procedure 3 using 2 M 
aq. NaOH (1 mL) in THF (1 mL, 0.3 M). Purified by reverse-phase HPLC to afford the title 
compound as a brown oil (4 mg, 4% over 2 steps). 1H NMR (400 MHz, CDCl3): δ 7.75-7.71 (m, 
1H), 7.72-7.69 (m, 1H), 7.64 (s, 1H), 7.59 (s, 1H), 7.37 (app t, J = 7.9 Hz, 1H), 7.30-7.23 (m, 
2H), 7.22-7.17 (m, 1H), 7.15-7.11 (m, 1H), 7.08-7.02 (m, 1H), 4.04 (s, 3H), 2.12 (s, 3H). CO2H 
proton not observed. 13C NMR (101 MHz, CDCl3): δ 170.8, 159.4, 137.4, 136.0, 130.9, 130.8, 
129.8, 127.7, 127.2, 123.7, 122.1, 121.0, 120.9, 120.3, 119.8, 117.2, 117.0, 110.3, 39.9, 9.6. υmax 
(neat): 3121, 3053, 2947, 1697, 1583 cm-1. HRMS: exact mass calculated for [M+H]+ 
(C20H18N3O3) m/z requires 348.1343, m/z found 348.1344. 
3-((6-Chloro-2-methyl-1H-indol-3-yl)oxy)benzoic acid (63). Prepared according to General 
Procedure 3 using ethyl 3-((6-chloro-2-methyl-1H-indol-3-yl)oxy)benzoate (94) (150 mg, 0.454 
mmol, 1 equiv.) and 2 M aq. NaOH (1 mL) in THF (1 mL, 0.4 M). Purified by reverse-phase 
HPLC to afford the title compound as an orange amorphous solid (30 mg, 22%). 1H NMR (400 
MHz, CO(CD3)2): δ 9.95 (br s, 1H), 7.44-7.41 (m, 1H), 7.28 (dd, J = 2.5, 1.5 Hz, 1H), 7.16 (app 
t, J = 7.9 Hz, 1H), 7.13 (d, J = 1.7 Hz, 1H), 6.94 (dd, J = 8.2, 2.6 Hz, 1H), 6.87 (d, J = 8.4 Hz, 
1H), 6.69 (dd, J = 8.4, 1.8 Hz, 1H), 2.05 (s, 3H). One exchangeable proton not observed. 13C 
NMR (101 MHz, CO(CD3)2): δ 167.3, 160.4, 134.7, 133.2, 130.6, 130.4, 127.5, 126.9, 123.9, 
120.7, 120.5, 118.4, 116.7, 112.0, 111.9, 10.1. υmax (neat): 3327, 3071, 1690, 1601, 1585, 1520 
cm-1. HRMS: exact mass calculated for [M+H]+ (C16H13ClNO3) m/z requires 304.0549, m/z 
found 304.0544. 
3-((6-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)oxy) benzoic acid (64). 
Prepared according to General Procedure 5 using (3-chlorophenyl)hydrazine hydrochloride (1.9 
g, 10.8 mmol, 1 equiv.) and ethyl 3-(2-oxopropoxy)benzoate (59) (2.4 g, 10.8 mmol, 1 equiv.) in 
EtOH (50 mL, 0.2 M). 1 g of the crude material was then used according to General Procedure 4 
using 4-bromo-1-methyl-1H-pyrazole (940 µL, 9.10 mmol, 3 equiv.), CuO (1.4 g, 18.2 mmol, 6 
equiv.), and K2CO3 (1.6 g, 11.8 mmol, 4 equiv.) in pyridine (15 mL, 0.7 M). Following aqueous 
work-up, the reaction mixture was then used in the next step without further purification. The 
crude material was used according to General Procedure 3 using 2 M aq. NaOH (30 mL) in THF 
(15 mL, 0.7 M). Purified by reverse-phase HPLC to afford the title compound as a cream 
amorphous solid (36 mg, 1% over 3 steps). 1H NMR (400 MHz, CO(CD3)2): δ 8.05 (s, 1H), 7.77-
7.67 (m, 2H), 7.62 (dd, J = 2.6, 1.5 Hz, 1H), 7.45 (app t, J = 7.9 Hz, 1H), 7.26 (dd, J = 8.3, 2.7 
Hz, 1H), 7.24-7.16 (m, 2H), 7.03 (dd, J= 8.4, 1.9 Hz, 1H), 4.03 (s, 3H), 2.21 (s, 3H). CO2H 
proton not observed. 13C NMR (101 MHz, CO(CD3)2): δ 167.3, 160.0, 137.2, 137.0, 133.1, 
131.1, 130.7, 129.4, 129.1, 128.3, 124.1, 121.3, 120.8, 120.4, 119.2, 118.6, 116.8, 111.0, 39.8, 
9.5. υmax (neat): 3122, 2949, 2921, 1696, 1606, 1584 cm
-1. HRMS: exact mass calculated for 
[M+H]+ (C20H17ClN3O3) m/z requires 384.0924, m/z found 384.0926. 
6-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (66). Prepared according to 
General Procedure 4 using 6-chloro-2-methyl-1H-indole (65) (300 mg, 1.81 mmol, 1 equiv.), 4-
bromo-1-methyl-1H-pyrazole (224 µL, 2.17 mmol, 1.2 equiv.), CuO (290 mg, 3.62 mmol, 2 
equiv.), and K2CO3 (325 mg, 2.36 mmol, 1.3 equiv.) in pyridine (3.5 mL, 0.5 M). Purified using 
silica chromatography, eluting with 0-30% EtOAc/petroleum ether, to afford the title compound 
as a brown amorphous solid (351 mg, 79%). 1H NMR (400 MHz, CDCl3): δ 7.56 (s, 1H), 7.50 
(s, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.13-7.08 (m, 1H), 7.06 (dd, J = 8.3, 1.9 Hz, 1H), 6.33 (s, 1H), 
4.01 (s, 3H), 2.27 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 139.4, 138.6, 137.3, 127.5, 127.2, 
126.8, 120.8, 120.5, 119.7, 110.1, 101.2, 39.8, 13.2. υmax (neat): 3119, 2943, 1715, 1676, 1607, 
1580 cm-1. HRMS: exact mass calculated for [M+H]+ (C13H13ClN3) m/z requires 248.0763, m/z 
found 248.0766. 
Methyl 6-((6-chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-
yl)methyl)picolinate (67). Prepared according to General Procedure 7 using trans-
bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (9 mg, 0.00959 mmol, 5 mol%), 3-
((6-bromopyridin-2-yl)methyl)-6-chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (97) 
(84 mg, 0.202 mmol, 1 equiv.), Mo(CO)6 (53 mg, 0.202 mmol, 1 equiv.), [tBu3PH]BF4 (12 mg, 
0.0414 mmol, 20 mol%), and DBU (45 µL, 0.303 mmol, 1.5 equiv.) in MeCN/MeOH (2.5 mL, 
1:4, 0.1 M). Purified using silica chromatography, eluting with 50-70% EtOAc/petroleum ether, 
to afford the title compound as a cream amorphous solid (61 mg, 76%). 1H NMR (400 MHz, 
CO(CD3)2): δ 7.96 (s, 1H), 7.88 (dd, J = 7.7, 1.0 Hz, 1H), 7.80 (app t, J = 7.7 Hz, 1H), 7.60 (s, 
1H), 7.56 (d, J = 8.4 Hz, 1H), 7.40 (dd, J = 7.8, 1.0 Hz, 1H), 7.07 (d, J = 1.7 Hz, 1H), 7.00 (dd, J 
= 8.4, 1.9 Hz, 1H), 4.32 (s, 2H), 4.01 (s, 3H), 3.93 (s, 3H), 2.36 (s, 3H). 13C NMR (151 MHz, 
CO(CD3)2): δ 166.5, 162.6, 148.6, 139.5, 138.4, 137.3, 137.0, 128.9, 127.7, 127.6, 126.5, 123.2, 
120.8, 120.4, 119.9, 110.7, 110.4, 52.6, 39.8, 34.0, 11.1. υmax (neat): 3086, 3057, 2950, 2917, 
2855, 1712, 1610, 1593, 1584 cm-1. HRMS: exact mass calculated for [M+H]+ (C21H20ClN4O2) 
m/z requires 397.1240, m/z found 397.1236. 
6-((6-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methyl) picolinic acid 
(68). Prepared according to General Procedure 3 using methyl 6-((6-chloro-2-methyl-1-(1-
methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methyl)picolinate (67) (50 mg, 0.126 mmol, 1 equiv.) 
and 2 M aq. NaOH (2 mL) in THF (2 mL, 0.1 M). Purified by reverse-phase HPLC to afford the 
title compound as a yellow oil (23 mg, 48%). 1H NMR (400 MHz, CO(CD3)2): δ 8.10-7.82 (m, 
3H), 7.61 (s, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.52 (dd, J = 7.6, 1.0 Hz, 1H), 7.08 (d, J = 1.8 Hz, 
1H), 7.01 (dd, J= 8.4, 1.9 Hz, 1H), 4.37 (s, 2H), 4.01 (s, 3H), 2.36 (s, 3H). CO2H proton not 
observed. 13C NMR (101 MHz, CO(CD3)2): δ 165.3, 161.9, 147.1, 139.7, 139.6, 137.3, 137.1, 
128.9, 127.7, 127.7, 127.5, 122.2, 120.9, 120.2, 119.9, 110.5, 110.4, 39.8, 33.4, 11.1. υmax (neat): 
3097, 2922, 1716, 1684, 1670, 1610, 1588 cm-1. HRMS: exact mass calculated for [M+H]+ 
(C20H18ClN4O2) m/z requires 383.1084, m/z found 383.1084.  
3-((6-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methyl) benzoic acid 
(69). Prepared according to General Procedure 4 using methyl 3-((6-chloro-2-methyl-1H-indol-
3-yl)methyl)benzoate (96) (345 mg, 1.10 mmol, 1 equiv.), 4-bromo-1-methyl-1H-pyrazole (227 
µL, 2.20 mmol, 2 equiv.), CuO (176 mg, 2.20 mmol, 2 equiv.), and K2CO3 (197 mg, 1.43 mmol, 
1.3 equiv.) in pyridine (3 mL, 0.4 M). Following aqueous work-up, the reaction mixture was then 
used in the next step without further purification. The crude material was used according to 
General Procedure 3 using 2 M aq. NaOH (2 mL) in THF (2 mL, 0.5 M). Purified by reverse-
phase HPLC to afford the title compound as a white amorphous solid (5 mg, 1% over 2 steps). 1H 
NMR (400 MHz, CO(CD3)2): δ 8.00-7.94 (m, 2H), 7.85 (d, J= 7.6 Hz, 1H), 7.62 (s, 1H), 7.52 
(dd, J = 7.7, 0.6 Hz, 1H), 7.45-7.36 (m, 2H), 7.08 (d, J = 1.7 Hz, 1H), 7.00 (dd, J = 8.4, 1.9 Hz, 
1H), 4.21 (s, 2H), 4.01 (s, 3H), 2.32 (s, 3H). CO2H proton not observed. 
13C NMR (151 MHz, 
CO(CD3)2): δ 167.7, 143.0, 139.6, 137.3, 136.6, 133.7, 131.6, 130.3, 129.4, 128.9, 128.1, 127.7, 
127.6, 120.8, 120.1, 119.9, 111.7, 110.5, 39.8, 30.6, 11.1. υmax (neat): 2922, 2554, 2361, 2153, 
1693, 1606, 1585 cm-1. HRMS: exact mass calculated for [M+H]+ (C21H19ClN3O2) m/z requires 
382.1131, m/z found 382.1134.  
3-((2-Methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methyl)benzoic acid (70). 
Prepared according to General Procedure 3 using methyl 3-((2-methyl-1-(1-methyl-1H-pyrazol-
4-yl)-1H-indol-3-yl)methyl)benzoate (100) (100 mg, 0.278 mmol, 1 equiv.) and 2 M aq. NaOH 
(2 mL) in THF (2 mL, 0.1 M). Purified by reverse-phase HPLC to afford the title compound as 
cream amorphous solid (10 mg, 10%). 1H NMR (400 MHz, CO(CD3)2): δ 7.99 (s, 1H), 7.92 (s, 
1H), 7.84 (d, J = 7.7 Hz, 1H), 7.59 (d, J = 0.6 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.44 (d, J = 7.2 
Hz, 1H), 7.38 (app t, J = 7.7 Hz, 1H), 7.14-6.95 (m, 3H), 4.21 (s, 2H), 4.01 (s, 3H), 2.33 (s, 3H). 
CO2H proton not observed.
 13C NMR (151 MHz, CO(CD3)2): δ 143.4, 139.1, 137.3, 135.2, 
133.8, 131.5, 130.3, 129.3, 129.0, 128.6, 128.0, 122.0, 120.7, 120.5, 118.8, 111.5, 110.6, 39.7, 
30.8, 11.0. One carbon not observed/coincident. υmax (neat): 3113, 3051, 2918, 2467, 1699, 
1605, 1584 cm-1. HRMS: exact mass calculated for [M-H]- (C21H18N3O2) m/z requires 344.1405, 
m/z found 344.1403.  
6-((2-Methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methyl)picolinic acid (71). 
Prepared according to General Procedure 3 using methyl 6-((2-methyl-1-(1-methyl-1H-pyrazol-
4-yl)-1H-indol-3-yl)methyl)picolinate (102) (50 mg, 0.139 mmol, 1 equiv.) and 2 M aq. NaOH 
(1 mL) in THF (1 mL, 0.1 M). Purified by reverse-phase HPLC to afford the title compound as a 
green gum (21 mg, 44%). 1H NMR (400 MHz, CDCl3): δ 10.50 (br s, 1H), 8.15 (d, J = 7.6 Hz, 
1H), 7.97 (app t, J = 7.8 Hz, 1H), 7.66 (s, 1H), 7.59 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 
7.5 Hz, 1H), 7.15 (d, J = 3.6 Hz, 2H), 7.11 (dd, J = 7.7, 4.1 Hz, 1H), 4.53 (s, 2H), 4.06 (s, 3H), 
2.28 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 163.4, 159.8, 144.8, 142.1, 138.4, 137.0, 135.6, 
128.3, 127.8, 127.7, 122.9, 122.3, 120.8, 120.2, 117.8, 110.2, 107.4, 39.7, 31.1, 11.0. υmax (neat): 
3103, 2950, 1725, 1716, 1696, 1670, 1616, 1588 cm-1. HRMS: exact mass calculated for [M-H]- 
(C20H17N4O2) m/z requires 345.1357, m/z found 345.1355.  
Methyl 6-bromopicolinate (73). Conc. H2SO4 (0.35 mL) was added to a round bottomed flask 
containing 6-bromopicoline (72) (1 g, 4.95 mmol, 1 equiv.) in MeOH (30 mL, 0.2 M). The 
reaction mixture was heated to reflux under N2 for 16 h, then cooled to 0 ¡C and 35% aq. 
NH4OH (1.6 mL) was added. The resulting solution was then concentrated under vacuum, 
dissolved in CH2Cl2 (50 mL), and washed with brine (50 mL). The organic layer was collected, 
dried (hydrophobic frit), and concentrated under vacuum to afford the title compound as a white 
amorphous solid (900 mg, 84%). 1H NMR (500 MHz, CDCl3): δ 8.09 (dd, J = 7.0, 1.5 Hz, 1H), 
7.73-7.66 (m, 2H), 4.00 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 164.4, 148.7, 142.1, 139.2, 
131.8, 124.0, 53.1. υmax (neat): 3000, 1719, 1678, 1562 cm
-1. HRMS: exact mass calculated for 
[M-H]- (C7H5BrNO2) m/z requires 217.9634, found 217.9632.  
Methyl 6-((3-bromophenyl)thio)picolinate (74). Methyl 6-bromopicolinate (73) (499 mg, 2.31 
mmol, 1.1 equiv.), Cs2CO3 (1.4 g, 4.36 mmol, 2 equiv.), and 3-bromothiophenol (218 µL, 2.12 
mmol, 1 equiv.) were dissolved in DMF (10 mL, 0.2 M) and stirred at 45 ¡C under N2 for 16 h. 
The reaction mixture was diluted with H2O (30 mL) and extracted using EtOAc (3 x 30 mL). 
The organic layers were combined, dried (hydrophobic frit), and concentrated under vacuum. 
Purified using silica chromatography, eluting with 10-40% EtOAc/petroleum ether, to afford the 
title compound as a white amorphous solid (260 mg, 38%). 1H NMR (400 MHz, CDCl3): δ 7.86 
(d, J = 7.6 Hz, 1H), 7.83-7.79 (m, 1H), 7.63 (app t, J = 7.9 Hz, 1H), 7.57-7.53 (m, 2H), 7.32 (d, J 
= 7.9 Hz, 1H), 7.06 (d, J = 8.1 Hz, 1H), 3.98 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 165.0, 
151.4, 143.9, 142.3, 140.7, 137.0, 136.2, 135.1, 128.8, 127.9, 126.7, 125.5, 55.9 υmax (neat): 
2960, 1724, 1560 cm-1. HRMS: exact mass calculated for [M-H]- (C13H9BrNO2S) m/z requires 
325.9666, m/z found 325.9666. 
6-((3-(1-Methyl-1H-pyrazol-4-yl)phenyl)thio)picolinic acid (75). Pd(OAc)2 (2 mg, 0.00893 
mmol, 1 mol%) was added to a solution of methyl 6-((3-bromophenyl)thio)picolinate (74) (280 
mg, 0.864 mmol, 1 equiv.), 1-methylpyrazole-4-boronic acid pinacol ester (269 mg, 1.29 mmol, 
1.5 equiv.), and S-Phos (707 mg, 1.72 mmol, 2 equiv.) in THF:H2O (0.8 mL, 7:1, 1 M) then 
heated to 50 ¡C for 16 h under N2. Following aqueous work-up, the reaction mixture was then 
used in the next step without further purification. The crude material was used according to 
General Procedure 3 using 2 M aq. NaOH (0.3 mL). Purified by reverse-phase HPLC to afford 
the title compound as a cream amorphous solid (37 mg, 14% over two steps). 1H NMR (400 
MHz, CDCl3): δ 7.90 (d, J = 7.3 Hz, 1H), 7.77 (s, 1H), 7.75-7.67 (m, 2H), 7.64 (s, 1H), 7.62-
7.55 (m, 1H), 7.51-7.42 (m, 2H), 7.24 (s, 1H), 3.95 (s, 3H). CO2H proton not observed. 
13C 
NMR (101 MHz, CDCl3): δ 138.6, 138.2, 136.3, 134.3, 132.7, 131.7, 130.6, 129.9, 128.9, 126.7, 
126.5, 121.6, 93.7, 42.4, 38.7. One carbon not observed/coincident. υmax (neat): 3140, 1682, 
1634, 1600, 1537, 1403 cm-1. HRMS: exact mass calculated for [M+H]+ (C17H14N3O2S) m/z 
requires 312.0801, m/z found 312.0801. 
4-Mercaptobutanoic acid (77). Prepared according to the literature procedure.39 A solution of 
4-bromobutyric acid (76) (3 g, 18.0 mmol, 1 equiv.) and thiourea (2 g, 29.8 mmol, 1.6 equiv.) in 
EtOH (26 mL, 0.7 M) was heated at reflux for 3 h, then allowed to return to room temperature 
and concentrated under vacuum. The residue was then dissolved in 7.5 M aq. NaOH (20 mL) and 
refluxed for 16 h. The reaction mixture was then cooled to 0 ¡C, acidified using 2 M aq. H2SO4, 
and extracted using CH2Cl2 (3 x 20 mL). The organics were combined, dried (hydrophobic frit) 
and concentrated under vacuum to afford the title compound as a colourless oil (1.7 g, 80%). 1H 
NMR (400 MHz, CDCl3): δ 10.07 (br s, 1H), 2.62-2.53 (m, 2H), 2.49 (t, J = 7.3 Hz, 2H), 1.95-
1.89 (m, 2H), 1.35 (t, J = 8.1 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ 179.5, 32.4, 28.6, 23.8. 
υmax (neat): 2960, 2550, 1703 cm
-1. HRMS: exact mass calculated for [M+H]+ (C4H9O2S) m/z 
requires 121.0318, m/z found 121.0315.  
4-((2-Oxopropyl)thio)butanoic acid (78). A solution of 4-mercaptobutanoic acid (77) (1.2 g, 
10.0 mmol, 1 equiv.) and DIPEA (4.4 mL, 25.0 mmol, 2.5 equiv.) in THF (30 mL, 0.3 M) was 
cooled to 0 ¡C, followed by the addition of chloroacetone (813 µL, 10.5 mmol, 1.05 equiv.) 
portionwise. The reaction mixture was then allowed to return to room temperature and stirred for 
16 h. The reaction was then diluted with EtOAc (50 mL) and washed with water (3 x 30 mL) and 
brine (1 x 30 mL). The organic layer was then collected, dried (hydrophobic frit), and 
concentrated under vacuum. Purified using silica chromatography, eluting with CH2Cl2, to afford 
the title compound as a clear oil (266 mg, 15%). 1H NMR (400 MHz, CDCl3): δ 8.14 (br s, 1H), 
3.20 (s, 2H), 2.52 (t, J = 7.2 Hz, 2H), 2.44 (t, J = 7.3 Hz, 2H), 2.27 (s, 3H), 1.96-1.89 (m, 2H). 
13C NMR (101 MHz, CDCl3): δ 203.7, 178.2, 41.0, 32.1, 30.6, 27.3, 23.2. υmax (neat): 2924, 
2529, 1701 cm-1. HRMS: exact mass calculated for [M+H]+ (C7H13O3S) m/z requires 177.0580, 
m/z found 177.0575.  
4-(2-Methyl-1H-indol-3-yl)butanoic acid (79). Prepared according to General Procedure 1 
using 4-((2-oxopropyl)thio)butanoic acid (78) (400 mg, 2.27 mmol, 1 equiv.) and 
phenylhydrazine hydrochloride (329 mg, 2.27 mmol, 1 equiv.) in tBuOH (15 mL, 0.2 M) with 
additional 1 M HCl in Et2O (0.4 mL) and AcOH (1 mL). Purified using reverse-phase HPLC to 
afford the title compound as a yellow oil (308 mg, 54%). 1H NMR (400 MHz, CDCl3): δ 8.09 (s, 
1H), 7.70-7.63 (m, 1H), 7.31-7.27 (m, 1H), 7.19-7.13 (m, 2H), 2.69 (t, J = 7.0 Hz, 2H), 2.53 (s, 
3H), 2.50 (t, J = 7.4 Hz, 2H) 1.85-1.78 (m, 2H). CO2H proton not observed. 
13C NMR (126 
MHz, CDCl3): δ 178.7, 140.0, 135.3, 130.5, 121.9, 120.3, 118.6, 110.6, 101.8, 35.1, 32.5, 24.7, 
12.2. υmax (neat): 3323, 2926, 2851, 1622, 1566 cm
-1. HRMS: exact mass calculated for [M-H]- 
(C13H14NO2S) m/z requires 248.0751, m/z found 248.0752.  
4-(2-Methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)butanoic acid (80). Prepared 
according to General Procedure 4 using 4-(2-methyl-1H-indol-3-yl)butanoic acid (79) (200 mg, 
0.803 mmol, 1 equiv.), CuO (128 mg, 1.60 mmol, 2 equiv.), K2CO3 (144 mg, 1.04 mmol, 1.3 
equiv.), and 1-methyl-4-bromopyrazole (248 µL, 2.40 mmol, 3 equiv.) in pyridine (2 mL, 0.4 M) 
to afford the title compound as a brown oil (4 mg, 2%). 1H NMR (400 MHz, CDCl3): δ 7.71 (dd, 
J = 6.5, 1.4 Hz, 1H), 7.60 (s, 1H), 7.54 (s, 1H), 7.22-7.13 (m, 3H), 4.03 (s, 3H), 2.73 (t, J = 7.1 
Hz, 2H), 2.52 (t, J = 7.4 Hz, 2H), 2.40 (s, 3H), 1.88-1.80 (m, 2H). CO2H proton not observed.
 
13C NMR (101 MHz, CDCl3): δ 102.5, 93.6, 92.6, 92.5, 92.3, 90.5, 89.9, 88.5, 88.2, 87.6, 85.5, 
83.6, 67.8, 66.6, 65.9, 64.0, 60.7. υmax (neat): 2910, 2600, 1719, 1580 cm
-1. HRMS: exact mass 
calculated for [M+H]+ (C17H20N3O2S) m/z requires 330.1271, m/z found 333.1267. 
4-((6-Chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)butanoic acid (81). 
Prepared according to General Procedure 1 using 4-((2-oxopropyl)thio)butanoic acid (78) (400 
mg, 2.27 mmol, 1 equiv.) and 3-chlorophenylhydrazine hydrochloride (406 mg, 2.27 mmol, 1 
equiv.) in tBuOH (15 mL, 0.2 M), with additional 1 M HCl in Et2O (1 mL) and AcOH (1 mL). 
The crude material was then used according to General Procedure 4 using CuO (225 mg, 2.81 
mmol, 1.2 equiv.), K2CO3 (252 mg, 1.83 mmol, 0.8 equiv.), and 1-methyl-4-bromopyrazole (437 
µL, 4.23 mmol, 1.9 equiv.) in pyridine (4 mL, 0.6 M). Purified by reverse-phase HPLC to afford 
the title compound as a brown oil (7 mg, 1% over 2 steps). 1H NMR (400 MHz, CDCl3): δ 7.60-
7.58 (m, 2H), 7.55 (s, 1H), 7.14 (dd, J = 8.3, 1.8 Hz, 1H), 7.11 (d, J = 1.6 Hz, 1H), 4.03 (s, 3H), 
2.71 (t, J = 7.1 Hz, 2H), 2.51 (t, J = 7.4 Hz, 2H), 2.38 (s, 3H), 1.87-1.80 (m, 2H). CO2H proton 
not observed.13C NMR (101 MHz, CDCl3): δ 176.6, 142.8, 138.2, 136.6, 136.6, 128.0, 127.6, 
121.0, 119.0, 110.0, 109.7, 102.5, 39.3, 34.8, 31.7, 24.3, 11.1. υmax (neat): 3409, 3000, 2900, 
1660 cm-1. HRMS: exact mass calculated for [M+H]+ (C17H19ClN3O2S) requires m/z 364.0881, 
found m/z 364.0878. 
Ethyl 6-((5-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (82). Prepared according to General 
Procedure 5 using ethyl 6-((2-oxopropyl)thio)picolinate (13) (1 g, 4.18 mmol, 1 equiv.) and (4-
chlorophenyl)hydrazine hydrochloride (749 mg, 4.18 mmol, 1 equiv.) in EtOH (25 mL, 0.2 M). 
Purified using silica chromatography, eluting with 0-50% EtOAc/cyclohexane, to afford the title 
compound as a brown amorphous solid (460 mg, 32%). 1H NMR (400 MHz, MeOD): δ 7.75 (dd, 
J = 7.6, 0.8 Hz, 1H), 7.59 (app t, J = 7.9 Hz, 1H), 7.36-7.32 (m, 2H), 7.11 (dd, J = 8.6, 2.0 Hz, 
1H), 6.75 (dd, J = 8.1, 0.8 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 2.49 (s, 3H), 1.42 (t, J = 7.1 Hz, 
3H). NH proton not observed. 13C NMR (101 MHz, MeOD): δ 164.7, 163.8, 147.5, 144.1, 137.7, 
134.6, 130.9, 126.0, 122.3, 121.7, 120.4, 116.8, 112.1, 95.4, 61.6, 13.1, 10.4. υmax (neat): 3263, 
1720, 1570, 1500 cm-1. HRMS: exact mass calculated for [M+H]+ (C17H16ClN2O2S) m/z requires 
347.0616, m/z found 347.0626.  
Ethyl 6-((7-chloro-2-methyl-1H-indol-3-yl)thio)picolinate (83). Prepared according to General 
Procedure 5 using ethyl 6-((2-oxopropyl)thio)picolinate (13) (550 mg, 2.30 mmol, 1 equiv.) and 
(2-chlorophenyl)hydrazine hydrochloride (412 mg, 2.30 mmol, 1 equiv.) in EtOH (12 mL, 0.2 
M). Purified using silica chromatography, eluting with 0-50% EtOAc/cyclohexane, to afford the 
title compound as a yellow amorphous solid (386 mg, 48%). 1H NMR (400 MHz, MeOD): δ 
7.74 (d, J = 7.2 Hz, 1H), 7.57 (app t, J = 7.9 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.15 (d, J = 7.6 
Hz, 1H), 7.02 (app t, J = 7.8 Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 2.52 (s, 
3H), 1.42 (t, J = 7.1 Hz, 3H). NH proton not observed. 13C NMR (101 MHz, MeOD): δ 164.6, 
163.8, 147.5, 143.8, 137.7, 133.2, 131.4, 122.4, 121.1, 120.9, 120.3, 116.3, 116.3, 96.9, 61.6, 
13.1, 10.3. υmax (neat): 3300, 3000, 1722, 1571 cm
-1. HRMS: exact mass calculated for [M+H]+ 
(C17H16ClN2O2S) m/z requires 347.0616, m/z found 347.0616. 
Ethyl 6-((6-fluoro-2-methyl-1H-indol-3-yl)thio)picolinate (84) and ethyl 6-((4-fluoro-2-
methyl-1H-indol-3-yl)thio)picolinate (85). Prepared according to General Procedure 5 using 
ethyl 6-((2-oxopropyl)thio)picolinate (13) (1 g, 4.18 mmol, 1 equiv.) and (3-
fluorophenyl)hydrazine hydrochloride (677 mg, 4.18 mmol, 1 equiv.) in EtOH (25 mL, 0.2 M). 
Purified using reverse-phase UPLC to afford ethyl 6-((6-fluoro-2-methyl-1H-indol-3-
yl)thio)picolinate (84) as a yellow amorphous solid (563 mg, 41%) and ethyl 6-((4-fluoro-2-
methyl-1H-indol-3-yl)thio)picolinate (85) as a yellow amorphous solid (332 mg, 24%). Ethyl 6-
((6-fluoro-2-methyl-1H-indol-3-yl)thio)picolinate (84): 1H NMR (400 MHz, MeOD): δ 7.72 (dd, 
J = 7.6, 0.9 Hz, 1H), 7.58-7.51 (m, 1H), 7.30 (dd, J = 8.6, 5.2 Hz, 1H), 7.09 (dd, J = 9.6, 2.2 Hz, 
1H), 6.84-6.79 (m, 1H), 6.74 (dd, J = 8.2, 0.9 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 2.46 (s, 3H), 
1.41 (t, J = 7.1 Hz, 3H). NH proton not observed. 13C NMR (101 MHz, MeOD): δ 164.6, 164.1, 
159.9 (d, 1JC-F = 236.1 Hz), 147.4, 142.8,(
 d, JC-F = 2.9 Hz), 137.7, 136.1 (
3
JC-F = 12.5 Hz), 126.0, 
122.4, 120.3, 118.3 (d, 3JC-F = 10.1 Hz), 108.2 (d,
 2
JC-F = 24.7 Hz ), 97.2 (d, 
2
JC-F = 26.5 Hz), 
95.6, 61.6, 13.1, 10.4. 19F NMR (376 MHz, MeOD): δ -123.5. υmax (neat): 3296, 3000, 1722, 
1627, 1573, 1560 cm-1. HRMS: exact mass calculated for [M+H]+ (C17H16FN2O2S) m/z requires 
331.0911, m/z found 331.0917. Ethyl 6-((4-fluoro-2-methyl-1H-indol-3-yl)thio)picolinate (85): 
1H NMR (400 MHz, MeOD): δ 7.74 (dd, J = 7.6, 0.9 Hz, 1H), 7.62-7.57 (m, 1H), 7.19 (d, J = 
8.0 Hz, 1H), 7.09-7.04 (m, 1H), 6.86 (dd, J = 8.1, 0.7 Hz, 1H), 6.71-6.66 (m, 1H), 4.42 (q, J = 
7.1 Hz, 2H), 2.47 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H). NH proton not observed. 13C NMR (101 MHz, 
MeOD): δ 165.0, 164.7, 155.9 (d, 1JC-F = 246.5 Hz), 147.2, 142.8, 139.0 (d, 
3
JC-F = 10.3 Hz), 
137.6, 122.4, 122.0 (d, 3JC-F = 7.6 Hz), 120.1, 117.7 (d, 
2
JC-F = 17.2 Hz), 107.2 (d, JC-F = 3.7 Hz), 
105.2 (d, 2JC-F = 19.2 Hz), 93.2, 61.6, 13.1, 10.1.
 19F NMR (376 MHz, DMSO-d6): δ -130.41. 
υmax (neat): 3300, 3000, 1718, 1573 cm
-1. HRMS: exact mass calculated for [M+H]+ 
(C17H16FN2O2S) m/z requires 331.0911, m/z found 331.0918. 
Ethyl 6-((2,6-dimethyl-1H-indol-3-yl)thio)picolinate (86) and ethyl 6-((2,4-dimethyl-1H-
indol-3-yl)thio)picolinate (87). Prepared according to General Procedure 5 using ethyl 6-((2-
oxopropyl)thio)picolinate (13) (1 g, 4.43 mmol, 1 equiv.) and m-tolylhydrazine hydrochloride 
(704 mg, 4.43 mmol, 1 equiv.) in EtOH (25 mL, 0.2 M). Purified using reverse-phase UPLC to 
afford ethyl 6-((2,6-dimethyl-1H-indol-3-yl)thio)picolinate (86) as a yellow amorphous solid 
(189 mg, 13%) and ethyl 6-((2,4-dimethyl-1H-indol-3-yl)thio)picolinate (87) as a yellow 
amorphous solid (156 mg, 11%). Ethyl 6-((2,6-dimethyl-1H-indol-3-yl)thio)picolinate (86): 1H 
NMR (400 MHz, MeOD): δ 7.70 (dd, J = 7.6, 0.9 Hz, 1H), 7.53-7.46 (m, 1H), 7.22 (d, J = 8.1 
Hz, 1H), 7.17 (s, 1H), 6.86 (dd, J = 8.0, 0.9 Hz, 1H), 6.72 (dd, J = 8.2, 0.9 Hz, 1H), 4.41 (q, J = 
7.1 Hz, 2H), 2.45 (s, 3H), 2.40 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H). NH proton not observed. 13C 
NMR (101 MHz, MeOD): δ 164.7, 147.3, 141.4, 137.5, 136.6, 131.4, 127.3, 122.5, 121.6, 120.1, 
117.1, 110.8, 95.0, 61.6, 20.3, 13.1, 10.3. One carbon not observed/coincident. υmax (neat): 3296, 
2950, 1720, 1574 cm-1. HRMS: exact mass calculated for [M+H]+ (C18H19N2O2S) requires m/z 
327.1162, found m/z 327.1161. Ethyl 6-((2,4-dimethyl-1H-indol-3-yl)thio)picolinate (87): 1H 
NMR (400 MHz, MeOD): δ 7.72 (dd, J = 7.6, 0.9 Hz, 1H), 7.60-7.54 (m, 1H), 7.21 (d, J = 8.1 
Hz, 1H), 7.02-6.96 (m, 1H), 6.82-6.73 (m, 2H), 4.42 (q, J = 7.1 Hz, 2H), 2.54 (s, 3H), 2.45 (s, 
3H), 1.41 (t, J = 7.1 Hz, 3H). NH proton not observed. 13C NMR (101 MHz, MeOD): δ 166.2, 
164.7, 147.3, 142.3, 137.7, 136.4, 129.5, 127.1, 122.5, 121.8, 121.4, 120.0, 108.9, 95.1, 61.6, 
17.5, 13.1, 10.3. υmax (neat): 3153, 2980, 1720, 1674, 1574 cm
-1. HRMS: exact mass calculated 
for [M+H]+ (C18H19N2O2S) requires m/z 327.1162, found m/z 327.1161. 
Ethyl 6-((6-methoxy-2-methyl-1H-indol-3-yl)thio)picolinate (88) and ethyl 6-((4-methoxy-2-
methyl-1H-indol-3-yl)thio)picolinate (89). Prepared according to General Procedure 5 using 
ethyl 6-((2-oxopropyl)thio)picolinate (13) (1 g, 4.18 mmol, 1 equiv.) and (3-
methoxyphenyl)hydrazine hydrochloride (732 mg, 4.18 mmol, 1 equiv.) in EtOH (25 mL, 0.2 
M). Purified using reverse-phase UPLC to afford ethyl 6-((6-methoxy-2-methyl-1H-indol-3-
yl)thio)picolinate (88) as a brown amorphous solid (521 mg, 36%) and ethyl 6-((4-methoxy-2-
methyl-1H-indol-3-yl)thio)picolinate (89) as a yellow amorphous solid (282 mg, 20%). Ethyl 6-
((6-methoxy-2-methyl-1H-indol-3-yl)thio)picolinate (88): 1H NMR (600 MHz, MeOD): δ 7.73 
(dd, J = 7.6, 0.8 Hz, 1H), 7.61-7.51 (m, 1H), 7.22 (d, J = 8.6 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 
6.77 (dd, J = 8.2, 0.8 Hz, 1H), 6.71 (dd, J = 8.6, 2.2 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 3.81 (s, 
3H), 2.44 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H). NH proton not observed. 13C NMR (151 MHz, 
MeOD): δ 164.6, 164.5, 156.7, 147.1, 140.9, 137.7, 136.9, 123.6, 122.6, 120.2, 118.0, 109.7, 
94.9, 94.7, 61.6, 54.7, 13.1, 10.3. υmax (neat): 3000, 1726, 1627 cm
-1. HRMS: exact mass 
calculated for [M+H]+ (C18H19N2O3S) requires m/z 343.1111, found m/z 343.1113. Ethyl 6-((4-
methoxy-2-methyl-1H-indol-3-yl)thio)picolinate (89): 1H NMR (600 MHz, MeOD): δ 7.72 (dd, 
J = 7.5, 0.8 Hz, 1H), 7.57 (app t, J = 7.9 Hz, 1H), 7.04 (app t, J = 7.9 Hz, 1H), 6.99 (dd, J = 8.1, 
0.6 Hz, 1H), 6.88 (dd, J = 8.2, 0.8 Hz, 1H), 6.51 (d, J = 7.7 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 
3.62 (s, 3H), 2.44 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H). NH proton not observed. 13C NMR (151 
MHz, MeOD): δ 166.4, 164.7, 153.5, 146.7, 140.6, 137.8, 137.3, 123.1, 122.4, 119.8, 118.6, 
104.4, 101.0, 94.3, 61.6, 54.4, 13.1, 10.2. υmax (neat): 3288, 2800, 1714, 1575, 1543, 1506 cm
-1. 
HRMS: exact mass calculated for [M+H]+ (C18H19N2O3S) requires m/z 343.1111, found m/z 
343.1112. 
Methyl 3-((6-chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)benzoate 
(90). Prepared according to General Procedure 4 using methyl 3-((6-chloro-2-methyl-1H-indol-
3-yl)thio)benzoate (46) (100 mg, 0.302 mmol, 1 equiv.), CuO (48 mg, 0.604 mmol, 2 equiv.), 
K2CO3 (54 mg, 0.393 mmol, 1.3 equiv.), and 1-methyl-4-bromopyrazole (94 µL, 0.906 mmol, 3 
equiv.) in pyridine (1 mL, 0.3 M). Purified using silica chromatography, eluting with 50% 
EtOAc/petroleum ether, to afford the title compound as a cream amorphous solid (74 mg, 59%). 
1H NMR (400 MHz, CDCl3): δ 7.83-7.82 (m, 1H), 7.74-7.72 (m, 1H), 7.63 (s, 1H), 7.61 (s, 1H), 
7.44 (d, J = 8.3 Hz, 1H), 7.23 (app t, J = 7.7 Hz, 1H), 7.19-7.15 (m, 2H), 7.11 (dd, J = 8.4, 1.8 
Hz, 1H), 4.05 (s, 3H), 3.87 (s, 3H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 166.9, 144.7, 
139.7, 139.2, 137.2, 130.9, 130.1, 129.0, 128.7, 128.1, 127.7, 127.0, 126.2, 122.1, 119.8, 119.3, 
110.6, 100.1, 52.4, 40.0, 11.8. υmax (neat): 3057, 2985, 2945, 2920, 2883, 2848, 1710, 1606, 
1570, 1539 cm-1. HRMS: exact mass calculated for [M+H]+ (C21H19ClN3O2S) m/z requires 
414.0850, m/z found 414.0851. 
3-((3-Bromophenyl)thio)-2-methyl-1H-indole (91). Prepared according to General Procedure 5 
using phenylhydrazine hydrochloride (592 mg, 4.08 mmol, 1 equiv.) and 1-((3-
bromophenyl)thio)propan-2-one (44) (1 g, 4.08 mmol, 1 equiv.) in EtOH (20 mL, 0.2 M). 
Purified using silica chromatography, eluting with 0-10% EtOAc/petroleum ether, to afford the 
title compound as a brown oil (1.2 g, 92%). 1H NMR (400 MHz, CDCl3): δ 8.30 (br s, 1H), 7.52 
(d, J = 7.8 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.23-7.19 (m, 1H), 7.18-7.11 (m, 3H), 7.00 (app t, J 
= 8.1 Hz, 1H), 6.98-6.92 (m, 1H), 2.52 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 142.1, 141.5, 
135.6, 130.1, 127.9, 127.7, 124.1, 123.0, 122.5, 121.0, 118.9, 110.9, 98.5, 12.3. One carbon not 
observed/coincident. υmax (neat): 3392, 3055, 2980, 1573, 1556 cm
-1. HRMS: exact mass 
calculated for [M+H]+ (C15H13BrNS) m/z requires 319.9925, m/z found 319.9931. 
Methyl 3-((2-methyl-1H-indol-3-yl)thio)benzoate (92). Prepared according to General 
Procedure 7 using trans-bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (183 mg, 
0.195 mmol, 5 mol%), 3-((3-bromophenyl)thio)-2-methyl-1H-indole (91) (1.2 g, 3.77 mmol, 1 
equiv.), Mo(CO)6 (995 mg, 3.77 mmol, 1 equiv.), [tBu3PH]BF4 (219 mg, 0.754 mmol, 20 
mol%), and DBU (844 µL, 5.66 mmol, 1.5 equiv.) in MeCN/MeOH (20 mL, 1:4, 0.2 M) to 
afford the title compound as a brown amorphous solid (1.03 g, 92%). 1H NMR (500 MHz, 
CDCl3): δ 8.49 (br s, 1H), 7.81 (s, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.34 
(d, J = 8.0 Hz, 1H), 7.22-7.09 (m, 4H), 3.86 (s, 3H), 2.50 (s, 3H). 13C NMR (126 MHz, CDCl3): 
δ 166.9, 141.4, 140.4, 135.6, 130.6, 130.1, 129.8, 128.7, 126.6, 125.8, 122.2, 120.8, 118.8, 110.8, 
52.1, 29.1, 12.1. υmax (neat): 3327, 2850, 1710 cm
-1. HRMS: exact mass calculated for [M-H]- 
(C17H14NO2S) m/z requires 296.0751, m/z found 296.0753. 
Methyl 3-((1,2-dimethyl-1H-indol-3-yl)thio)benzoate (93). Prepared according to General 
Procedure 6 using methyl 3-((2-methyl-1H-indol-3-yl)thio)benzoate (92) (200 mg, 0.673 mmol, 
1 equiv.), NaH 60% w/w (54 mg, 1.35 mmol, 2 equiv.), and MeI (84 µL, 1.35 mmol, 2 equiv.) in 
THF (3 mL, 0.2 M). Purified using silica chromatography, eluting with 10% EtOAc/petroleum 
ether, to afford the title compound as a pale yellow amorphous solid (71 mg, 34%). 1H NMR 
(500 MHz, CDCl3): δ 7.87 (s, 1H), 7.74 (dd, J = 7.6, 1.2 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.38 
(d, J = 8.2 Hz, 1H), 7.28 (app t, J = 7.1 Hz, 1H), 7.24-7.11 (m, 3H), 3.90 (s, 3H), 3.79 (s, 3H), 
2.56 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 166.9, 143.1, 140.8, 137.3, 130.7, 129.9, 129.6, 
128.8, 126.7, 125.8, 122.0, 120.7, 118.9, 109.3, 97.5, 52.2, 30.5, 11.0. υmax (neat): 2949, 1722, 
1572, 1527 cm-1. HRMS: exact mass calculated for [M+H]+ (C18H18NO2S) m/z requires 
312.1053, m/z found 312.1055. 
Ethyl 3-((6-chloro-2-methyl-1H-indol-3-yl)oxy)benzoate (94). Prepared according to General 
Procedure 1 using (3-chlorophenyl)hydrazine hydrochloride (1.6 g, 9.01 mmol, 1 equiv.) and 
ethyl 3-(2-oxopropoxy)benzoate (59) (2 g, 9.01 mmol, 1 equiv.) in tBuOH (90 mL, 0.1 M) with 
additional 1 M HCl in Et2O (27 mL) and AcOH (10 mL). Purified by silica chromatography, 
eluting with 10% EtOAc/petroleum ether, to afford the title compound as a pale brown 
amorphous solid (845 mg, 28%). 1H NMR (600 MHz, CDCl3): δ 7.72-7.65 (m, 2H), 7.62 (dd, J 
= 2.5, 1.6 Hz, 1H), 7.31 (app t, J = 8.0 Hz, 1H), 7.29 (d, J = 1.6 Hz, 1H), 7.13 (d, J = 8.4 Hz, 
1H), 7.10 (dd, J = 8.3, 2.6 Hz, 1H), 6.98 (dd, J = 8.4, 1.8 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 2.32 
(s, 3H), 1.36 (t, J = 7.1 Hz, 3H). NH proton not observed. 13C NMR (151 MHz, CDCl3): δ 166.4, 
159.2, 133.6, 132.2, 129.6, 129.4, 127.9, 125.1, 123.1, 120.7, 120.3, 119.8, 118.2, 116.6, 111.0, 
61.2, 14.4, 10.4. υmax (neat): 3350, 2982, 1713, 1701, 1585 cm
-1. HRMS: exact mass calculated 
for [M+H]+ (C18H17ClNO3) m/z requires 332.0862, m/z found 332.0867. 
 3-(3-Bromobenzyl)-6-chloro-2-methyl-1H-indole (95). Prepared according to General 
Procedure 8 using 3-bromobenzaldehyde (442 mg, 2.39 mmol, 1.1 equiv.), 6-chloro-2-methyl-
1H-indole (65) (360 mg, 2.17 mmol, 1 equiv.), Et3SiH (451 µL, 2.83 mmol, 1.3 equiv.), and 
TFA (249 µL, 3.26 mmol, 1.5 equiv.) in CH2Cl2 (10 mL, 0.2 M). Purified using silica 
chromatography, eluting with 0-5% EtOAc/petroleum ether, to afford the title compound as a 
white amorphous solid (587 mg, 73%). 1H NMR (600 MHz, CO(CD3)2): δ 10.10 (br s, 1H), 7.38 
(s, 1H), 7.34-7.28 (m, 3H), 7.23 (d, J = 7.7 Hz, 1H), 7.18 (app t, J = 7.8 Hz, 1H), 6.93 (dd, J = 
8.5, 1.8 Hz, 1H), 4.06 (s, 2H), 2.42 (s, 3H). 13C NMR (151 MHz, CO(CD3)2): δ 145.7, 134.5, 
131.9, 131.0, 129.5, 128.3, 128.1, 126.8, 122.8, 119.9, 119.7, 111.1, 110.2, 30.0, 11.6. One 
carbon not observed/coincident. υmax (neat): 3409, 3053, 2911, 2850, 1692, 1613, 1593, 1567 
cm-1. HRMS: exact mass calculated for [M+H]+ (C16H14BrClN) m/z requires 337.9948, m/z 
found 337.9947.  
Methyl 3-((6-chloro-2-methyl-1H-indol-3-yl)methyl)benzoate (96). Prepared according to 
General Procedure 7 using trans-bis(acetato)bis[o-(di-o-tolylphosphino)benzyl] dipalladium(II) 
(77 mg, 0.0821 mmol, 5 mol%), 3-(3-bromobenzyl)-6-chloro-2-methyl-1H-indole (95) (551 mg, 
1.65 mmol, 1 equiv.), Mo(CO)6 (436 mg, 1.65 mmol, 1 equiv.), [tBu3PH]BF4 (96 mg, 0.330 
mmol, 20 mol%), and DBU (370 µL, 2.48 mmol, 1.5 equiv.) in MeCN/MeOH (10 mL, 1:4, 0.2 
M). Purified using silica chromatography, eluting with 0-15% EtOAc/petroleum ether, to afford 
the title compound as a pale yellow amorphous solid (348 mg, 67%). 1H NMR (400 MHz, 
CO(CD3)2): δ 10.11 (br s, 1H), 7.89 (s, 1H), 7.81-7.78 (m, 1H), 7.53-7.44 (m, 1H), 7.37 (app t, J 
= 7.7 Hz, 1H), 7.33-7.28 (m, 2H), 6.91 (dd, J = 8.4, 1.9 Hz, 1H), 4.13 (s, 2H), 3.83 (s, 3H), 2.43 
(s, 3H). 13C NMR (101 MHz, CO(CD3)2): δ 167.3, 143.5, 137.2, 134.4, 133.8, 131.2, 129.9, 
129.3, 128.4, 127.7, 126.8, 119.9, 119.8, 111.2, 110.6, 52.2, 30.3, 11.7. υmax (neat): 3328, 2945, 
2896, 1705, 1621, 1608 cm-1. HRMS: exact mass calculated for [M+H]+ (C18H17ClNO2) m/z 
requires 316.0913, m/z found 316.0914.  
3-((6-Bromopyridin-2-yl)methyl)-6-chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-
indole (97). Prepared according to General Procedure 8 using 6-bromopyridine-2-carbaldehyde 
(91 mg, 0.489 mmol, 1.2 equiv.), 6-chloro-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole 
(66) (100 mg, 0.406 mmol, 1 equiv.), Et3SiH (84 µL, 0.529 mmol, 1.3 equiv.), and TFA (47 µL, 
0.610 mmol, 1.5 equiv.) in CH2Cl2 (2 mL, 0.2 M). Purified using silica chromatography, eluting 
with 0-50% EtOAc/petroleum ether, to afford the title compound as a yellow oil (94 mg, 56%). 
1H NMR (400 MHz, CO(CD3)2): δ 7.96 (s, 1H), 7.60 (s, 1H), 7.57 (app t, J = 7.7 Hz, 1H), 7.51 
(d, J = 8.4 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.08 (d, J = 1.6 Hz, 1H), 
7.02 (dd, J = 8.4, 1.9 Hz, 1H), 4.23 (s, 2H), 4.01 (s, 3H), 2.33 (s, 3H). 13C NMR (101 MHz, 
CDCl3): δ 163.8, 141.9, 140.4, 139.5, 137.3, 137.1, 128.9, 127.6, 126.2, 122.4, 120.8, 120.2, 
119.9, 110.5, 110.3, 39.8, 33.5, 11.1. One carbon not observed/coincident. υmax (neat): 3114, 
2921, 1612, 1582, 1554 cm-1. HRMS: exact mass calculated for [M+H]+ (C19H17BrClN4) m/z 
requires 417.0297, m/z found 417.0294.  
2-Methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (98). Prepared according to General 
Procedure 4 using 2-methyl-1H-indole (1 g, 7.63 mmol, 1 equiv.), 4-bromo-1-methyl-1H-
pyrazole (1.2 mL, 11.4 mmol, 1.5 equiv.), CuO (1.2 g, 15.3 mmol, 2 equiv.), and K2CO3 (1.4 g, 
9.92 mmol, 1.3 equiv.) in pyridine (10 mL, 0.8 M). Purified using silica chromatography, eluting 
with 0-30% EtOAc/petroleum ether, to afford the title compound as a brown amorphous solid 
(679 mg, 42%). 1H NMR (400 MHz, CDCl3): δ 7.58 (s, 1H), 7.57-7.52 (m, 1H), 7.50 (s, 1H), 
7.17-7.07 (m, 3H), 6.37 (s, 1H), 4.01 (s, 3H), 2.31 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 
138.9, 137.7, 137.4, 128.3, 127.4, 121.2, 120.3, 120.2, 119.7, 110.0, 101.2, 39.8, 13.3. υmax 
(neat): 3114, 3051, 2984, 2941, 2919, 1612, 1586, 1560 cm-1. HRMS: exact mass calculated for 
[M+H]+ (C13H14N3) m/z requires 212.1182, m/z found 212.1182.  
3-(3-Bromobenzyl)-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (99). Prepared 
according to General Procedure 8 using 2-bromobenzaldehyde (90 mg, 0.486 mmol, 1.02 
equiv.), 2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (98) (100 mg, 0.474 mmol, 1 equiv.), 
Et3SiH (84 µL, 0.529 mmol, 1.1 equiv.), and TFA (47 µL, 0.610 mmol, 1.3 equiv.) in CH2Cl2 (2 
mL, 0.2 M). Purified using silica chromatography, eluting with 20-50% EtOAc/petroleum ether, 
to afford the title compound as a yellow gum (165 mg, 89%). 1H NMR (400 MHz, CDCl3): δ 
7.60 (s, 1H), 7.53 (s, 1H), 7.46-7.38 (m, 2H), 7.30 (d, J = 7.8 Hz, 1H), 7.21-7.04 (m, 5H), 4.09 
(s, 2H), 4.02 (s, 3H), 2.26 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 144.1, 138.3, 137.5, 134.6, 
131.4, 130.0, 129.1, 128.1, 127.6, 127.1, 122.6, 121.5, 120.4, 120.0, 118.2, 110.5, 109.9, 39.8, 
30.3, 11.1. υmax (neat): 3116, 3053, 2986, 2941, 2919, 1614, 1582, 1569 cm
-1. HRMS: exact 
mass calculated for [M+H]+ (C20H19BrN3) m/z requires 382.0736, m/z found 382.0737. 
Methyl 3-((2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methyl) benzoate (100). 
Prepared according to General Procedure 7 using trans-bis(acetato)bis[o-(di-o-
tolylphosphino)benzyl]dipalladium(II) (19 mg, 0.0202 mmol, 5 mol%), 3-(3-bromobenzyl)-2-
methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (99) (150 mg, 0.395 mmol, 1 equiv.), Mo(CO)6 
(104 mg, 0.395 mmol, 1equiv.), [tBu3PH]BF4 (23 mg, 0.0793 mmol, 20 mol%), and DBU (88 
µL, 0.593 mmol, 1.5 equiv.) in MeCN/MeOH (2.5 mL, 1:4, 0.2 M). Purified using silica 
chromatography, eluting with 50-70% EtOAc/petroleum ether, to afford the title compound as a 
yellow oil (111 mg, 78%). 1H NMR (400 MHz, CDCl3): δ 7.99 (s, 1H), 7.85 (d, J = 7.8 Hz, 1H), 
7.59 (s, 1H), 7.53 (s, 1H), 7.41 (app t, J = 8.0 Hz, 2H), 7.31 (app t, J = 7.7 Hz, 1H), 7.18-7.01 
(m, 3H), 4.16 (s, 2H), 4.01 (s, 3H), 3.90 (s, 3H), 2.27 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 
167.4, 142.1, 138.3, 137.5, 134.5, 133.1, 130.3, 129.6, 128.6, 128.1, 127.6, 127.3, 121.5, 120.4, 
120.0, 118.2, 110.8, 109.9, 52.2, 39.8, 30.6, 11.1. υmax (neat): 3116, 3051, 2949, 2919, 1718, 
1608, 1584 cm-1. HRMS: exact mass calculated for [M+H]+ (C22H22N3O2) m/z requires 
360.1707, m/z found 360.1705.  
3-((6-Bromopyridin-2-yl)methyl)-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (101). 
Prepared according to General Procedure 8 using 6-bromopyridine-2-carbaldehyde (91 mg, 
0.489 mmol, 1.03 equiv.), 2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (98) (100 mg, 
0.474 mmol, 1 equiv.), Et3SiH (84 µL, 0.529 mmol, 1.1 equiv.), and TFA (47 µL, 0.610 mmol, 
1.3 equiv.) in CH2Cl2 (2 mL, 0.2 M). Purified using silica chromatography, eluting with 20-60% 
EtOAc/petroleum ether, to afford the title compound as a yellow gum (158 mg, 85%). 1H NMR 
(400 MHz, CDCl3): δ 7.58 (s, 1H), 7.52 (s, 1H), 7.44 (dd, J = 6.6, 1.5 Hz, 1H), 7.34 (app t, J= 
7.7 Hz, 1H), 7.27 (d, J = 8.7 Hz, 1H), 7.19-7.05 (m, 3H), 6.98 (dd, J = 7.5, 0.7 Hz, 1H), 4.29 (s, 
2H), 4.01 (s, 3H), 2.27 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 163.2, 141.3, 138.9, 138.3, 
137.5, 135.2, 128.0, 127.5, 125.4, 121.7, 121.2, 120.3, 120.2, 118.2, 110.0, 109.1, 39.8, 33.2, 
11.1. υmax (neat): 3114, 3051, 2921, 1616, 1582, 1554 cm
-1. HRMS: exact mass calculated for 
[M+H]+ (C19H18BrN4) m/z requires 383.0689, m/z found 383.0686.  
Methyl 6-((2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methyl)picolinate (102). 
Prepared according to General Procedure 7 using trans-bis(acetato)bis[o-(di-o-
tolylphosphino)benzyl] dipalladium(II) (17 mg, 0.0181 mmol, 5 mol%), 3-((6-bromopyridin-2-
yl)methyl)-2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-1H-indole (101) (140 mg, 0.367 mmol, 1 
equiv.), Mo(CO)6 (97 mg, 0.367 mmol, 1 equiv.), [tBu3PH]BF4 (21 mg, 0.0724 mmol, 20 
mol%), and DBU (82 µL, 0.550 mmol, 1.5 equiv.) in MeCN/MeOH (2.5 mL, 1:4, 0.1 M). 
Purified using silica chromatography, eluting with 50-100% EtOAc/petroleum ether, to afford 
the title compound as a yellow oil (55 mg, 42%). 1H NMR (400 MHz, CDCl3): δ 7.94 (d, J = 7.6 
Hz, 1H), 7.62 (app t, J = 7.8 Hz, 1H), 7.59 (s, 1H), 7.53 (s, 1H), 7.42 (d, J = 7.4 Hz, 1H), 7.22-
7.04 (m, 4H), 4.44 (s, 2H), 4.04 (s, 3H), 4.02 (s, 3H), 2.27 (s, 3H). 13C NMR (101 MHz, CDCl3): 
δ 166.2, 162.2, 147.4, 138.4, 137.5, 135.2, 128.1, 127.5, 125.9, 122.8, 121.7, 120.4, 120.2, 
118.3, 110.0, 109.3, 53.1, 39.9, 33.6, 11.1. One carbon not observed/coincident. υmax (neat): 
3118, 3090, 3001, 2943, 2919, 2855, 1716, 1617, 1591 cm-1. HRMS: exact mass calculated for 
[M+H]+ (C21H21N4O2) m/z requires 361.1659, m/z found 361.1660.  
Bis-pNPP Inhibition Assay. Molecules were tested for their ability to inhibit autotaxin activity 
using the Autotaxin Inhibitor Screening Kit (Cayman Chemical) with modifications to the 
manufacturerÕs protocol. Briefly, in a 96 well plate 20 ng/mL autotaxin was incubated with 1 
mM bis-pNPP at 30 ¡C for 30 min in 50 mM Tris-HCl buffer (pH 8.5) containing 10 mM CaCl2 
and 0.02% triton X. Liberated bis-p-nitrophenol was measured using a Wallac Victor2 1420 
multilabel counter (Perkin Elmer, Beaconsfield, UK) in absorbance mode at 405 nm. The 
background was determined by incubating bis-pNPP in the absence of enzyme. Activity of the 
compounds was determined by subtracting the average background optical density from all 
results and expressing the compound activity as a percentage of the enzyme-substrate reaction in 
the absence of compound. Compounds were screened against autotaxin at a single concentration 
or using a dose response curve. Single concentration screens were carried out at an inhibitor 
concentration of 30 µM; samples which showed inhibition of 60% or greater were considered to 
be active and progressed to further testing. Dose response curves were performed in the 
concentration range of 30 nM to 30 µM, or 2 nM to 50 µM, ten point curves. Compounds which 
showed inhibition of less than 60% at 30 µM or a IC50 value greater than 30 µM were considered 
inactive. Data was expressed as mean ± SEM, plotted, and the IC50 values were calculated using 
Graph Pad Prism version 6.00 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com.  
LPC Choline Release Assay. All biochemical studies were performed with hATX. ATX 
lysoPLD activity was measured by choline release from LPC. 20 nM ATX (prepared from HEK 
293 Flp-In cells) was incubated with 150 µM LPC(18:1) in a final volume of 100 µL buffer 
containing 50 mM Tris pH 7.4, 0.01% Triton X-100, 50 mM CaCl2, 1 Unit ml
-1 choline oxidase, 
2 Unit ml-1 HRP, 2 mM homovanilic acid (HVA). The relative amount of released choline was 
measured by HVA fluorescence in a 96-well plate (Corning). Fluorescent intensity was 
determined at λex/λem = 320/450 nm every 30 seconds for 90 minutes with a Fluorostar plate 
reader (BMG Labtech). All compounds were screened initially from 400 nM to 100 µM, n = 3, 
and categorized into one of four IC50 categories: (i) <1 µM; (ii) 1-10 µM; (iii) 10-20 µM; (iv) 
>30 µM. Further screening of active compounds was then carried out from 0.5 nM to 10 µM, n = 
2. Data analysis was performed using GraphPad Prism version 6.00 for Windows, GraphPad 
Software, La Jolla California USA, www.graphpad.com. 
ATX production and crystallization. ATX from rat (rATX) and human (hATX) was produced 
in HEK293 Flip-In cells as described previously.40 For co-crystallization of rATX with 51, 51 
was first mixed with a 10M excess of rATX (3.5mg ml-1) and incubated for 30 min. Crystals 
were obtained at room temperature (293 K) in a 24-well optimization screen (18-22% PEG 3350, 
01-04 M NaSCN and 0.1-0.4 M NH4I) by mixing 1 µl of protein:inhibitor solution and 1 µl of 
reservoir solution. The structure presented here is from a crystal obtained from a 24-well 
containing the following conditions: 20% PEG 3350, 0.2 M NH4I, 0.1 M NaSCN. 
Crystallographic data and methods. 
X-ray diffraction data was collected at SLS on beamline PXIII. The crystallographic diffraction 
data was recorded on a PILATUS detector to a resolution of 2.4  for the ATX-51 complex, 
PDB reference 5LQQ. The data was processed and integrated with XDS,41 and scaled with 
AIMLESS.42 The structure was determined by molecular replacement using PHASER43 with the 
structure of ATX (PDB 2XR9) as the search model. Model building and subsequent refinement 
were performed iteratively with COOT,35 REFMAC,44 and PDB_REDO.45  
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